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The Relationship Between FAM5C SNP (rs10920501) Variability in Women with  
 
Coronary Heart Disease, Metabolic Syndrome, and Inflammation 
 
Jennifer L. Cline 
ABSTRACT 
The leading cause of death among women is coronary heart disease (CHD), a 
multifactorial disease with polygenic heritability estimated at 50%. 
Polymorphisms in the family with sequence similarity 5, member C’ (FAM5C)  
gene have been associated with myocardial infarction (MI), and one single-
nucleotide polymorphism (SNP) has partially accounted for linkage in an acute 
coronary syndrome subset. The linkage peak on FAM5C corresponds directly 
with a quantitative trait locus for the inflammatory biomarker monocyte 
chemoattractant protein 1, as well as a linkage peak to metabolic syndrome 
(MetS). Metabolic syndrome increases the risk of developing CHD, and MI has 
been positively associated with elevated inflammatory biomarkers. This study 
was designed as a descriptive pilot gene association study. The purpose was to 
investigate the variability of the FAM5C SNP (rs10920501) in a cohort of women 
with documented CHD. It also examined the association between the variability 
of the FAM5C SNP (rs10920501), MetS, inflammatory markers, and the 
association with early onset CHD in the presence or absence of MI. A subset of 
91 women was derived from an earlier study of women randomized to either a 
  vi 
gender-tailored or traditional cardiac rehabilitation program. The results indicated 
the T allele of FAM5C SNP rs10920501 has a strong protective effect in women 
with a history of MI. Women with a history of MI and the heterozygous (AT) 
genotype had a mean age of onset of CHD at 62 years, compared to the 
homozygous wild type (AA) with a mean age of onset at 55 years, (F (3, 34) = 
5.00, p < .01). No women in this study with the homozygous variant (TT) had an 
MI, further demonstrating the protective effective of the T allele. The genotype of 
FAM5C SNP rs10920501 explains approximately seven percent of the variability 
of age of onset of CHD in women who have had an MI, while holding body mass 
index (BMI) and smoking history constant. There was no significant relationship 
between FAM5C SNP (rs109320501) and MetS or any inflammatory biomarkers 
in this sample. In conclusion, FAM5C remains a gene of interest in a complex 
disease process.   
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Chapter One  
 
Introduction 
 
It is estimated that 16 million American adults have CHD (Lloyd-Jones et 
al., 2009). In 2004, one in 30 women died from breast cancer. In comparison, in 
the same year, one in six women died from CHD, making it the leading cause of 
death for women (Rosamond et al., 2008). Coronary heart disease is a complex 
disease with numerous risk factors. Many family and twin studies have examined 
the importance of an environmental and genetic association. Adding to the 
complexity, the interaction between the risk factors frequently is not additive, but 
exponential. This is further complicated by the polygenic heritability of CHD, 
which can exceed 50% (Lusis, Mar, & Pajukanta, 2004; Hardy & Singleton, 
2009). Large genome-wide association scans for various risk factors have failed 
to identify a single locus which accounts for the large population variation, 
suggesting multi-gene involvement (Lusis, Mar, & Pajukanta).    
The chromosomal region 1q25-31 has been identified as a susceptibility 
region for MI in two independent populations (Connelly et al., 2008; Hauser et al., 
2004). The Genomewide Scan for Early-Onset Coronary Artery Disease Study 
(GENECARD), which included 422 families, identified a 40 megabase region of 
linkage to CHD on chromosome 1q25-31 (Hauser et al., 2004). A priori 
stratification by sibling pairs with acute coronary syndrome (ACS), revealed a 
well defined linkage peak (n = 228 families, logarithm base 10 of odds (LOD) =  
  2 
2.17, at peak microsatellite marker D1S2589/D1S518) (Hauser et al., 2004). This 
linkage peak correlates exactly with the linkage peak for the inflammatory 
biomarker monocyte chemoattractant protein 1 (MCP-1) (LOD = 4.27), at peak 
microsatellite marker D1S1589 identified by the Framingham Heart Study 
(Dupuis et al., 2005) and with the linkage peak (LOD = 2.59, D1S1589/D1S518) 
for MetS in the Insulin Resistance Atherosclerosis Study Family Study (Mercuro 
et al.) (Langefeld et al., 2004). A SNP found within the first intron of the tumor 
necrosis factor superfamily 4 gene (TNFSF4) (rs3850641), has also been found 
to reside within the chromosome 1q linkage peak and has been strongly 
associated with MetS and MI in two independent populations (Wang et al., 2005). 
This genetic overlap gives strong support to a CHD susceptibility gene in this 
region. 
A strong association with MI was identified with SNPs in the 3’ end of the 
FAM5C gene, which was confirmed within an independent CAD case-control 
dataset (Connelly et al., 2008). One SNP (rs10920501) in this region displayed 
linkage and association in both samples. Gene expression of rs10920501 was 
correlated with the FAM5C genotype in 83 human aortic tissue samples, of which 
58 were unique. Aorta samples were collected from heart transplant donors. The 
inheritance of the T allele of rs10920501 was significantly associated with the 
reduction in the expression of FAM5C in the aorta. Proliferating aortic smooth 
muscle cells and human endothelial cells were cultured and reverse transcriptase 
PCR identified FAM5C expression in both cell types. It was shown that FAM5C 
transcript levels decrease with increasing passage of aortic smooth muscle cell, 
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suggesting that the level of gene expression may play a role in proliferation and 
senescence of this cell type (Connelly et al.). Higher expression of the FAM5C in 
the cells that make up the artery may be related to an increased risk of MI. 
FAM5C is localized to the mitochondria, which has been associated with 
cell proliferation and apoptosis (Connelly et al., 2008). The location of FAM5C 
within the mitochondria was the basis for the hypothesis that FAM5C played a 
role in regulating cell proliferation and migration, and ultimately the 
pathophysiology of the vulnerable atherosclerotic plaque (Connelly et al., 2008). 
The relationship between FAM5C, inflammatory biomarkers, and MetS 
remains to be clarified and is the basis for the current study (see the Conceptual 
Model in Figure 1). Understanding the role of FAM5C may aid in the 
development of new biomarkers to assess disease risk and response to 
treatment, identify susceptibility genes for at-risk individuals, and help guide 
pharmacogenetic studies to improve interventions to moderate risk. Coronary 
heart disease is a complex disease caused by a combination of genetic effects 
and environmental influences. Coronary heart disease is preventable, but will 
require the elucidation of the genetic predisposition to address all possible 
targets for risk reduction. 
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Figure 1. Conceptual Model to Evaluate FAM5C SNP rs10920501 
 
Note: Abbreviations; MI: myocardial infarction, ACS: acute coronary syndrome, 
MetS: Metabolic Syndrome, hs-CRP: high-sensitivity C-reactive protein, 
ICAM-1: intercellular adhesion molecule-1, IL-6: interleukin-6, TNF-α: 
tumor necrosis factor-α. 
 
Statement of the Problem 
More women than men die from CHD and their outcomes are poorer than 
men. Alternative targets for risk reduction may improve CHD outcomes in 
women. Investigating genetic interactions expressed through inflammatory 
biomarkers will help explain their role in endovascular physiology and provide a 
target for risk stratification and treatment.  
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Statement of the Purpose 
The purpose of the current study was to explore the variability of the 
FAM5C SNP (rs10920501) in a cohort of women with documented CHD, to 
assess the relationship between FAM5C SNP rs10920501, MetS, and 
inflammatory markers, and to evaluate if FAM5C SNP rs10920501 variability was 
associated with early onset CHD.  
Rationale for Single SNP Study 
Due to the exploratory nature of the study, a single SNP was selected 
based on work by Connelly et al. (2008). The FAM5C gene has been proposed 
as a novel MI susceptibility gene by Connelly et al. A single SNP (rs10920501) 
within the gene has partially accounted for linkage in the GENECARD ACS 
subset and was associated with MI in CATHGEN sample. Gene expression was 
also correlated with this SNP in human aortic cells (Connelly et al., 2008). 
Therefore, the SNP (rs10920501) is considered to be a strong predictor of the 
FAM5C gene and has been selected for the current study. 
This SNP has a minor allele frequency of .20 in the European (Utah 
residents with ancestry from northern and western Europe) population, .32 in the 
Han Chinese population, .23 in Japanese population, and .172 in the Sub-
Saharan African population (International HapMap Project, 2008).  
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 Specific Aims 
Aim One 
Describe the distribution of the genotype in the FAM5C SNP (rs10920501) 
in a cohort of women with documented CHD.  
Rationale One. Coronary heart disease is the leading cause of death and 
disability in women in the United States. Coronary heart disease is a disease with 
complex gene-environment interactions, in which heritability can exceed 50%. 
Numerous genome-wide studies have been performed focusing on the most 
severe phenotype of CHD. The FAM5C has been linked by genome-wide and 
independent case control analysis to MI and ACS (Connelly et al., 2008; Hauser 
et al., 2004).  
In previous trials of FAM5C, males were over-represented, comprising 
1533 of 2186 subjects or > 70% of the population (Connelly et al., 2008). Very 
little sex-specific genetic or biomarker data is available for review (Novack, 
Cutlip, Jotkowitz, Lieberman, & Porath, 2008). Historically, the literature has 
reported higher mortality rates and poorer outcomes for women with CHD, which 
warrants further investigation. 
Aim Two 
Investigate the associations between the variability in the genotype in the 
FAM5C SNP (rs10920501), MetS, and inflammatory biomarkers among 
women with documented CHD. 
Rationale Two. There is overlap of genetic screens in independent data 
sets, which have validated linkage on chromosome 1 to inflammatory 
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biomarkers, MetS and MI (Dupuis et al., 2005; Langefeld et al., 2004; Hauser et 
al., 2004; Wang et al., 2005). The association between FAM5C rs10920501, 
inflammatory biomarkers, and MetS within this region remains to be clarified.  
 A female cohort is appropriate, in as much as MetS is a contributor to 
inflammation and is found more frequently in elderly female populations 
(Feinberg, Schwartz, & Behar, 2008; Zeller et al., 2005; Levantesi et al., 2005, 
Marroquin et al., 2004). An all female cohort will not permit examination of 
gender differences, but given the under representation of females in previous 
studies, the use of an all female sample in the proposed work is seen as an 
asset. 
Aim Three 
Evaluate the association between FAM5C SNP (rs10920501) and early onset 
CHD in women.  
Rationale Three. The parent study has reported that in a cohort of women 
enrolled in cardiac rehabilitation (CR), younger women were more likely than 
older women to have been diagnosed with a MI (Beckie, Fletcher, Beckstead, 
Schocken, & Evans, 2008). They also had poorer physiologic profiles. 
Specifically, younger women had higher BMIs, larger waist circumference, 
increased body fat, and lower high-density lipoprotein cholesterol (HDL-C) levels 
compared to older women. Younger women were more likely to smoke and 
express a high degree of psychological distress (Beckie et al., 2008). 
Additionally, Connelly et al. (2008) has shown that the odds ratio and p value 
improved in when stratifying the sample by age (T allele, p= 0.009, OR= 0.539).  
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Innovation 
 The future of genetics is based on exploring the polygenic basis of 
complex disease and the gene-environment interaction. The novelty of this study 
is that it explores a polymorphism of FAM5C in a cohort of women, while taking 
into account MetS and inflammatory biomarkers. The results of this study 
promote the integration of genetics into the nursing process by providing 
additional research data on the influence of genetics on complex diseases. This 
study highlights the importance of gene-gene and gene-gender interactions. 
Adding to the current knowledge base, this study should facilitate nurses’ ability 
to provide education on the hereditary risk of developing disease, counsel about 
genetic testing, and manage disease based on genetic testing, all of which 
ultimately translate into patient care. The study may also impact 
pharmacogenetics of CHD, as the knowledge of the genetic variants and 
mechanisms of CHD evolve. As the knowledge base of the genetics of CHD 
expands, all areas of prevention, detection, diagnosis, and treatment will be 
positively affected.  
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Chapter Two 
 
Review of Literature 
 
Introduction 
The pathogenesis of CHD has multiple origins. In this chapter, a 
systematic review of the literature is presented to address the genetic and 
environmental factors that interact to influence the development and progression 
of CHD. The chapter begins with a description of the magnitude of CHD in 
women and the importance of prevention. That is followed by a review of the role 
of MetS and its link to inflammation. Inflammatory biomarkers, which were 
included in the parent study, are also explored. A review of landmark genome-
wide association studies (GWAS) relative to CHD and an appraisal of the novel 
FAM5C gene are then presented. Lastly, gaps in current knowledge are 
reviewed.  
Coronary Heart Disease and Women 
 Worldwide, CHD is the single largest cause of death among women 
(Lloyd-Jones et al., 2009). Nearly half a million women die each year of 
cardiovascular disease (CVD) (Lloyd-Jones et al., 2009). Women have higher 
rates of recurrent MI and age-adjusted mortality after the first MI than men 
(Chandra, 1998; Rogers, 2008). Women 40 years and older have a 43% 
increased risk of death within the first five years following the first MI, compared 
with men who have a 33% increased risk (Lloyd-Jones et al., 2009). The human 
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and economic toll of CHD has reached epic proportions. The estimated cost of 
CHD in 2010 is approximately $177 billon dollars (Lloyd-Jones et al., 2010). 
Fortunately, the vast majority of CHD in women is preventable (Mosca et al., 
2007).  
 Differences in lifestyle fail to explain the disparity in the incidence of CHD 
between genders. Traditional risk factors have been shown to have a high 
heritability (Lusis, Mar, & Pajukanta, 2004), some of which show gender biases 
(McCarthy, 2007). For example, there is considerable evidence for sex 
differences in the heritability of body mass and diabetes. Body mass has been 
shown to be 50% heritable in women, compared to 35% in men (Pilia et al., 
2006). This suggests a possible gender-gene interaction (McCarthy; Pilia, 2006; 
Schousboe, 2004; Kuusisto, 2008).  
The biological etiology of the gender-based differences in the 
development of CHD may have many sources. The first is the sex-linked 
chromosomes. Most X-linked traits are more common in men, since a woman 
would have to inherit mutations in both copies of her X-chromosome. Second, 
the rate of cumulative risk factors is different between genders. In a study by 
Leander et al. (2007), smoking was found to interact with family history among 
women in the development of MI, but not among men. There is growing evidence 
that genes interact with traditional risk factors in the development of CHD. Third, 
the effect of sex hormones, including estrogen and testosterone, differ between 
the genders (McCarthy, 2007). This is seen abruptly at the onset of menopause, 
when women lose the protective benefits of sex hormones and are at greater risk 
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for metabolic abnormalities (McCarthy). Menopause leads to a more atherogenic 
lipid profile (Derby et al., 2009), central adiposity (Toth, Tchernof, Sites, & 
Poehlman, 2000), and an overall increase in MetS corrected for age (Poehlman, 
2002; Levantesi et al., 2005; Zeller et al., 2005). Lastly, there are anatomical and 
physiological differences that must be considered, including differences in fat 
distribution and insulin resistance (Mittendorfer, 2005), cardiovascular function 
(Peterson, 2008), and gene expression (Northoff et al., 2008; Rinn & Snyder, 
2005).            
 In 2007, the American Heart Association published guidelines on CHD 
prevention in women (Mosca et al., 2007). The guidelines recognized the role of 
novel risk factors and screening technologies in CHD prevention. The expert 
panel recommended focused research on different time periods during a 
woman’s life, such as adolescence, pregnancy, and menopause. The guidelines 
suggested that events unique to a particular life stage might be additive to 
traditional cardiac risk factors. The panel also recognized that some women are 
at increased risk for future events, due to known disease or multiple risk factors. 
The panel suggested that these women should be targeted for aggressive 
preventative therapy, including control of hypertension, obesity, and stress. The 
AHA guidelines acknowledged that additional research on the role of genetics in 
risk factor stratification and the responsiveness to interventions was important 
(Mosca).   
 
 
  12 
Metabolic Syndrome 
Metabolic syndrome has been defined as the presence of three or more of 
the following risk factors: waist circumference > 88 cm in women and > 102 cm in 
men, triglycerides > 150 mg/dL, HDL-C < 50 mg/dL in women and < 40 mg/dL in 
men, blood pressure > 130/85 mmHg, and fasting glucose > 100 mg/dL or the 
diagnosis of diabetes (Grundy et al., 2006). Estimates suggest that MetS is 
present in 25% of all adults in the United States and in 40% of those > 60 years 
old (Adult Treatment Panel III, 2001). Studies have shown that the MetS 
population is more likely to be female and older (Feinberg, Schwartz, & Behar, 
2008; Zeller et al., 2005; Levantesi et al., 2005). An analysis of the Myocardial 
Ischemia Reduction with Aggressive Cholesterol Lowering trial found patients 
meeting the criteria for MetS had a 19% incidence of death, nonfatal MI, cardiac 
arrest, or recurrent unstable myocardial ischemia during the 16-week trial, as 
opposed to 14% in patients without MetS (Schwartz, Olsson, Szarek, & Sasiela, 
2005). Metabolic syndrome is associated with dysregulated adipose tissue, which 
is attributable to inflammation with increased levels of several cytokines 
(Gustafson, Hammarstedt, Andersson, & Smith, 2007). This increases the risk for 
cardiovascular atherosclerosis and markedly worsens long-term prognosis 
(Espinola-Klein et al., 2007). 
There is emerging evidence linking obesity to the proinflammatory state of 
MetS. Adipose tissue is now recognized as an endocrine organ (Kershaw & Flier, 
2004). Adipose tissue produces numerous cytokines that contribute to the 
inflammatory status. Leptin has been associated with total obesity (Friedman & 
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Halaas, 1998), whereas others such as interleukin-6 (IL-6), tumor necrosis factor-
alpha (TNF-α), plasminogen activator-1 (PAI-1), and adiponectin are more 
closely linked to abdominal obesity (Friedman, 1998; Fain, 2004; Alessi, 1997; 
Lihn, 2004; Pitsavos, 2008; Rexrode, 2003). Abdominal adiposity is the strongest 
predictor of an elevated c-reactive protein (CRP) in older women, whereas total 
percentage of body fat is the strongest predictor in men (Valentine, Vieira, 
Woods, & Evans, 2009). In adipose tissue, macrophages are the primary source 
of TNF-α (Suganami, Nishida, & Ogawa, 2005). Macrophages are the primary 
mediators of the immune response and represent up to 40% of the infiltrated 
cells in adipose tissue (Weisberg et al., 2003). Also, TNF-α has been shown to 
impair insulin signaling in adipocytes and skeletal muscle (Ruan & Lodish, 2004). 
It has been hypothesized that these cytokines, or “adipokines”, are the link 
between obesity and other components of MetS (Hivert, 2008; You, 2008).  
Metabolic syndrome has been characterized by a state of chronic 
inflammation. It is accepted that adipose tissue functions as an endocrine organ, 
which further stimulates cytokine production (Hivert et al., 2008). In a recent 
study of postmenopausal women with coronary heart disease, 74% of the women 
met Adult Treatment Panel (ATP) III criteria for MetS (Brown et al., 2008). As 
obesity and sedentary lifestyles are reaching epic proportions, understanding the 
interaction of MetS and inflammatory biomarkers has become imperative to 
improve the early identification, treatment, and prevention of CHD (Hivert et al., 
2008). 
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Inflammatory Biomarkers 
Metabolic syndrome has emerged as one of the main contributors to 
atherosclerosis and has been positively associated with elevated inflammatory 
markers. Elevated levels of circulating inflammatory markers have been 
associated with cardiovascular risk factors and all stages of the atherosclerotic 
process, including endothelial dysfunction, plaque development, plaque 
instability, and ultimately acute coronary syndromes (Bermudez, Rifai, Buring, 
Manson, & Ridker, 2002; Athyros, Kakafika, Karagiannis, & Mikhailidis, 2008).  
An inflammatory marker that has received considerable attention is CRP. 
In several prospective studies, CRP has been shown to be an independent risk 
factor for CHD (Ridker, 2008; Ridker, 2005; Ray, 2005; Lowe, 2006) and MetS 
(Pischon, 2008; Alizadeh Dehnavi, 2008; Mattsson, 2008). Data has confirmed 
that CRP is a strong independent predictor of mortality among ACS patients who 
were treated with early revascularization (Mueller et al., 2002; Zairis et al., 2002).  
It has been shown that CRP is related to the size of myocardial infarct (De Sutter 
et al., 2001). In addition, intravascular ultrasound has shown in patients having 
an acute MI, CPR levels correlate with the presence of plaque rupture (Sano et 
al., 2003). Also, increased temperature at unstable plaques, measured with an 
invasive thermogenic catheter, has been related to elevated CRP levels 
(Stefanadis et al., 2000). In stable post-MI patients, an elevated CRP level is 
associated with a significantly higher risk for recurrent nonfatal MI or fatal 
coronary events (75% higher in the highest quartile versus the lowest quartile of 
high-sensitivity C-reactive protein (hs-CRP)) (Zebrack et al., 2002; Kosuge et al., 
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2008). Based on this data, it has been suggested that CRP levels are predictive 
of short and long term cardiac events.      
C-reactive protein is produced primarily in the liver in response to IL-6 
secretion. Interleukin-6 is a key regulator of the inflammatory response and is 
produced in the adipose tissue. C-reactive protein production occurs with a 
synergistic enhancement of interleukin one (IL-1) and TNF-α (Athyros, Kakafika, 
Karagiannis, & Mikhailidis, 2008). C-reactive protein can also be found in the 
endothelium of atherosclerotic plaques, smooth muscle cells, macrophages, and 
adipocytes (Athyros et al.). C-reactive protein stimulates the expression of 
adhesion cells, tissue factor, MCP-1, and plasminogen activator one (PAI-1). C-
reactive protein activates leukocytes and the complement system, and reduces 
the bioavailability of nitric oxide. Data suggest that CRP itself potentially attracts 
monocytes and facilitates the uptake of low-density lipoprotein cholesterol (LDL-
C) by macrophages (Zwaka, Hombach, & Torzewski, 2001). In smooth muscle 
cells, CRP up-regulates the Ang type 1 receptor and stimulates smooth muscle 
cell proliferation and reactive oxygen species production (Athyros et al.). C-
reactive protein and related biomarkers exert a pathogenic role in the 
atherosclerotic process. This may be reflective of an ongoing cytokine-mediated 
acute phase response initiated by the innate immune system.  
Cytokines are regulatory proteins that have been implicated in the process 
of inflammation. Among the main cytokines are IL-1, IL-6, interleukin-10, TNF-α, 
and MCP-1 (Introna, Colotta, Sozzani, Dejana, & Mantovani, 1994; Mantovani, 
Bussolino, & Dejana, 1992; Mantovani, Bussolino, & Introna, 1997). Interleukin-1 
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and IL-6 regulate the production of reactant proteins, including CRP. Interleukin-6 
may increase plaque instability by driving the expression of matrix 
metalloproteinases, TNF-α, and MCP-1 (Schieffer et al., 2000). 
Elevated IL-6 levels in healthy males correlated with an increased risk of 
future MI independent of CRP (Ridker, 2000). In the Fragmin and/or Early 
Revascularization During Instability in Coronary Artery Disease trial, elevated IL-
6 was associated with a higher six and twelve month mortality, independent of 
troponin and CRP levels (Lindmark, Diderholm, Wallentin, & Siegbahn, 2001). In 
a recent study, IL-6 levels have been shown to be predictive of the onset of an 
acute ST-segment elevation MI and have prognostic value for future cardiac 
mortality within two years of the event (Tan, 2008). This data suggests that IL-6 
may identify patients with more severe events. However, the application of IL-6 
as a routine biomarker for inflammation has been limited by large variation of IL-6 
levels within and between individuals and few confirmatory studies (Picciotto et 
al., 2008; Cava, Gonzalez, Pascual, Navajo, & Gonzalez-Buitrago, 2000). 
Tumor necrosis factor-α is a major pro-inflammatory cytokine that has 
been shown to be significantly elevated in the setting of an acute MI compared to 
controls (Goswami, Rajappa, Mallika, Shukla, & Kumar, 2009). Tumor necrosis 
factor-α has also been implicated in myocardial dysfunction and remodeling after 
coronary events (Nian, Lee, Khaper, & Liu, 2004). In the Cholesterol and 
Recurrent Events study, recurrent coronary events after MI were associated with 
higher TNF-α levels compared with controls (Ridker, 2000). In as much as TNF-α 
has been elevated in acute events independent of other risk factors, it has been 
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suggested that this inflammatory biomarker should be a target for treatment 
(Ridker).  
Cellular adhesion molecules (CAMs) play a pivotal role in the interactions 
between leukocytes, platelets, and the vascular endothelium. In cardiovascular 
disorders, CAMs are involved in atherogenesis and atherosclerotic plaque 
progression (Haverslag, Pasterkamp, & Hoefer, 2008). Mulvihill, Foley, Murphy, 
Crean, and Walsh (2000) measured CAMs in patients with ACS at presentation 
and then after 3, 6, and 12 months. Cellular adhesion molecule levels increased 
within 10 hours of chest pain onset and remained elevated for 6 months, 
suggesting the inflammatory stimulus remains sustained (Mulvihill et al.). In 
patients with unstable angina undergoing coronary stenting, intercellular 
adhesion molecule (ICAM) and CRP levels were prognostic of those patients at 
higher risk of having a cardiac event (Doo et al., 2005). However, it was 
suggested that CRP may play a direct role in promoting the inflammatory 
component of atherosclerosis by inducing the expression of ICAM-1 (Doo et al., 
2005). Recent reports from the Nurses’ Health Study and Health Professionals 
Follow-up Study found, compared to controls, subjects with MetS had a 
significantly increased relative risk of CHD. After adjustment for MetS, CRP, and 
ICAM-1 remained an independent predictor of CHD in men (Pischon et al., 
2008).  
Inflammation has been implicated as a central contributor of the initiation 
and progression of CHD. Inflammatory biomarkers may have prognostic value in 
identifying those at risk for future events. Beckie, Beckstead and Groer (2009) 
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recently published data from the parent study demonstrating that a moderate-
intensity exercise program positively affected inflammatory biomarkers and some 
components of MetS. However, data remains conflicting regarding which 
biomarker or combination of biomarkers are the most suitable for diagnosis or 
prognosis of CHD. Through additional research, select markers of inflammation 
may emerge as targets to direct interventions to minimize CHD risk.        
Genetic Susceptibility of Coronary Heart Disease 
Advances in Molecular Genetics 
Completion of the Human Genome Project, the ability to perform large 
scale genetic assays, and the study of gene expression have all assisted in 
advancing the discovery of susceptibility genes for complex diseases. The 
purpose of the Human Genome Project was to identify all the genes in human 
DNA and to determine the sequence of the three billion base pairs that make up 
human DNA (National Institutes of Health (NIH), 2009). Due to rapid 
technological advancements, the project was completed ahead of schedule in 
2003. However, only twenty to twenty-five thousand, or 1.5-2%, of identified 
genes code for proteins (Human Genome Project Information, 2008). Proteins 
carry out most of the biochemical activities in a cell and determine how the 
organism functions. For example, proteins are vital to the immune response, 
metabolism, and even behavior (Human Genome Project Information, 2008). 
Little is known about the other 98% of genes (NIH, 2009). 
The creation of HapMap in 2005 was a step towards bridging the gap 
between knowing where the genes are located and understanding the genetic 
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basis of human health and disease. HapMap is a catalog of human variation or 
haploytpes in the human genome (International HapMap Project, 2009).  
HapMap data have accelerated the search for genes associated with disease 
and been instrumental in finding the genes related to conditions such as obesity 
and macular degeneration (Hamsten & Eriksson, 2008).  
The development of high-throughput genotyping assays can be 
considered the accelerant for an explosion of genetic studies and gene 
identification. In the early 1980’s, few genes had been identified. Since that time, 
there has been a steady annual increase, with over 1800 genes identified in 2005 
alone (Human Genome Project Information, 2008). 
Initially, genetic studies were aimed at establishing a linkage between 
genes. This was established with microsatellites, which are short tandem repeat 
segments (Damani & Topol, 2007). Genetic linkage occurs when specific loci or 
alleles are inherited together. Linkage studies can be challenging to perform 
because large numbers of families with multiple affected members must be 
recruited. Every subject’s DNA is evaluated with 400 microsatellite markers 
spaced every 10 cM (or 1 million base pairs) across the genome. The genomes 
are then evaluated for a “linkage peak” or extensive allele sharing among family 
members or affected subjects as compared to controls (Damani & Topol, 2007). 
A significant peak is described as a logarithm of odds ratio score (LOD score)     
> 3.0, which is a logarithm (base 10) of the likelihood ratio (Hartl & Jones, 2005). 
A LOD score > 3.0 suggests that the gene is near or within the microsatellite 
marker (Hartl & Jones, 2005). Identifying genes that cause a specific disease 
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within a distance of 1 million base pairs has remained difficult (Damani & Topol, 
2007). In general, linkage studies will have a low resolution as they are reporting 
large chromosomal regions with a few million base pairs (Hartl & Jones, 2005). 
The strongest linkage signals will come from recessive and highly penetrant 
diseases and it can take years to perform fine-mapping to determine the exact 
gene that is involved (Hartl & Jones). 
Currently, most genotyping is performed with genome-wide association 
studies. These studies utilize SNPs to establish association with disease (Human 
Genome Project Information, 2008). Single-nucleotide polymorphisms are 
differences in a single base of DNA. SNPs account for greater than 90% of 
human variation, and occur every 100 to 300 bases. Various SNPs can be 
inherited together, which are called haplotypes. A “tagging SNP” is used to 
identify a haplotype block or gene region that has a different distribution between 
the disease group and the control. Each region can then be studied with 
additional fine mapping, to determine which variants in the gene contribute to the 
disease (Human Genome Project Information, 2008). A standard microchip array 
can evaluate 500,000 to 1 million SNPs, which has significantly lowered the cost 
of gene identification (Hamsten & Eriksson, 2008). The cost of DNA chip 
technology has dropped by three orders of magnitude over the last 15 years 
(NIH, 2009). Collectively, these advances have made GWASs for complex 
diseases possible. 
Genome-wide studies are a comprehensive, unbiased approach for 
identifying genes involved in disease. Early genome-wide studies focused on the 
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MI phenotype, which is the most severe manifestation of CHD (Topol, Smith, 
Plow, & Wang, 2006; Connelly et al., 2008). Since that time, many well-powered 
genome-wide studies have identified loci that are associated with the increased 
the risk of CHD and MI (Kathiresan, 2009). Several of the most relevant studies 
are reported here (see Table 1).  
Linkage Studies 
Eight of the most pivotal genome-wide linkage studies focusing on CHD 
and MI are reviewed here (Table 1). Each study has implicated a different 
susceptibility gene for CHD. Only one locus was replicated from one study to the 
next, each occurring within a population of premature CHD and MI. Linkage was 
observed on chromosome 2 (2p12) for both premature CHD and MI (LOD 2.70) 
in the British Heart Foundation Study (Samani et al., 2005), and it corresponded 
directly with a linkage peak previously identified by Wang et al. (2004) (LOD 
3.82), and is very close to the region identified by Pajukanta et al. (2000) 
(2q21.1-22). This strengthens the evidence that a locus on chromosome 2 is 
associated with CHD risk (Samani et al., 2005). There has been vast speculation 
on why there has not been more uniform replication between genome-wide 
studies. Possibilities include genetic and phenotypic heterogeneity, population 
stratification, low statistical power and the use of different software programs, 
differences in the ethnic backgrounds of subjects, and variation of study designs 
(Heng, 2008).  
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Table 1 
 
Summary of Landmark Genome-wide Linkage Studies for Coronary Heart  
Disease 
Author Year Study 
population 
Number 
of 
Affected 
Subjects 
Mean 
Age 
Primary locus Phenotype 
Pajukanata 2000 Finnish 364 < 55M 
< 65F 
2q21.2 Premature 
CHD 
& MI 
 
Francke 2001 Mauritian 240 53 16p13 CHD & MI 
 
Broeckel 2002 European 513 52 14 CHD & MI 
 
Harrap 2002 Australian 122 62 2q36 CHD & MI 
 
Helgadottir 2004 Icelandic 713   - 13q12 MI 
 
Wang 2004 American 1,613 44 1p34 Premature 
CHD 
& MI 
 
Hauser 2004 American 985 
 
< 51M 
< 56F 
 
3q13 
 
ACS 
Samani 2005 British 4,175 
CHD 
1,776 MI 
53 
52 
2p11 Premature 
CHD 
& MI 
Note: Abbreviations; CHD: coronary heart disease, MI: myocardial infarction, 
ACS: acute coronary syndrome, M: male, F: female.  
 
Helgadottir et al. (2004) carried out a genome-wide study on 296 Icelandic 
families, including 713 individuals with MI. The study identified two haplotypes 
spanning the gene arachidonate 5-lipoxygenase-activating protein (ALOX5AP) 
under the linkage peak at 13q12-13 that are associated with MI and leukotriene 
B4 production (peak LOD 2.86 in females with MI). The first haplotype encodes 
for 5-lipoxygenase activating protein (FLAP). FLAP is an important regulator of 
leukotriene inflammatory mediators. Males had the strongest association with the 
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at-risk haplotype, with a nearly two-fold increase in risk for MI and stroke 
(Helgadottir et al., 2004). The same haplotype was later confirmed in a Scottish 
cohort to be significantly associated with stroke in males (Lohmussaar et al., 
2005), and with MI in an unpublished Cleveland study (Topol, Smith, Plow, & 
Wang, 2006). From the original genome-wide scan, Helgadottir et al. performed 
additional fine mapping techniques to determine that the five to seven SNP 
marker haplotype, leukotriene A4 hydrolase (LTA4H), accounted for a linkage 
peak at 12q22 (Helgadottir et al., 2006). Helgadottir et al. also found an ancestry-
specific risk of MI, whereas African Americans had three-fold greater risk for MI 
than subjects with European American ancestry (Helgadottir et al.). This study 
set three important precedents. First, it demonstrated that two different genes in 
the same inflammatory pathway could be associated with disease via a single 
genome-wide scan. Second, it demonstrated that FLAP has been implicated in 
the pathogenesis of atherosclerosis and is an important biomarker for CHD, and 
lastly ancestry-specific risk for MI was demonstrated for a particular gene. 
Wang et al. (2004) conducted genome-wide studies seeking an 
association with premature CHD. Wang et al. yielded one significant 
susceptibility loci (LRP8) for MI on chromosome 1p34-36 (LOD = 11.68, p < 10-
12) in 1,613 white pedigrees. A population-based association replication study 
identified a single SNP (rs5174) with the LRP8 gene as a significant prognostic 
indicator of an increased risk of premature CHD and MI (p = .036 for CHD and p 
= .048 for MI after Bonferroni correction) (Shen et al., 2007). The precise role 
LRP8 plays in the development of an MI remains under investigation. However, it 
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has been hypothesized that LDL binds to LRP8, which activates the 
phosphorylation of LRP8. This increases activation of the p38 mitogen-activated 
protein kinase, leading to platelet aggregation, thrombosis, and potentially MI 
(Shen et al.; Hauser et al., 2004). 
Of the genome-wide linkage studies that identified susceptibility loci for 
CHD and MI, three suggested linkage to type two diabetes mellitus (T2DM) 
(Broeckel et al., 2002; Francke et al., 2001; Harrap et al., 2002). Broeckel et al. 
performed a GWAS on 513 families to identify regions linked to MI and related 
risk factors known to be under genetic control. Subjects were identified by 
screening 93,500 charts at seven cardiac centers throughout Germany. Families 
were included if at least one sibling had a documented MI, angiographic CHD, or 
previous coronary revascularization. Genotyping was performed at a spacing of 
10 cM, with additional fine mapping at chromosome 14. Linkage with MI was 
identified at chromosome 14 (LOD = 3.9, p < .05). Additional risk factor analysis 
was carried out to characterize the locus. Serum concentrations of lipoprotein (a) 
showed linkage at the known apolipoprotein (a) locus on chromosome 6 (LOD = 
26.99) and a new locus on chromosome 1 (LOD = 3.8). There was suggestion of 
linkage for T2DM on chromosome 2 (LOD = 2.96). There was no overlap with the 
susceptibility locus for MI (Broeckel et al., 2002).  
The first evidence of a susceptibility loci for CHD, hypertension (HTN), and 
T2DM in the context of MetS was presented by Francke et al. in 2001. They 
conducted a 10cM genome scan with 403 microsatellite markers in 99 families. 
Families were recruited through a proband with early onset CHD (< 52 years of 
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age), and criteria for family inclusion included MI or T2DM. In a second step, 
additional fine mapping was performed on three chromosomal regions where 
linkage was found. Data suggested a linkage with chromosome 16p13-pter, 
which partially overlapped a peak for HTN. At the same locus, there was nominal 
linkage with T2DM in 35 large families of Indian origin. Region 8q23 showed 
modest linkage between HTN and T2DM (LOD = 2.55, p = .00058), and a 
previously identified region on 3q27 was replicated revealing linkage between 
CHD and MI (LOD = 2.13, p = .0009) (Francke et al., 2001).   
 Harrap et al. (2002) performed a genome-wide study on sibling pairs to 
identify a susceptibility locus for ACS. Approximately 6000 admissions to cardiac 
units from 8 Melbourne hospitals were screened for inclusion. Probands were 
enrolled if they had a documented MI before the age of 70 and had an affected 
sibling with the same history. Genotyping was completed at a 10 cM resolution. 
One locus on chromosome 2q36-37.3 showed linkage with ACS (LOD = 2.63, p 
< .00001), which was replicated with independent markers (LOD = 2.64). This 
region overlaps with genes encoding for the insulin receptor substrate-1 (IRS1), 
the HDL binding protein (HDLPB), and the locus NIDDMI which has been linked 
to T2DM. However, only one sibling pair in the present study had T2DM, which 
did not explain the results (Harrap et al.). This study highlighted the importance 
of the comparison of pathways and processes implicated in different diseases. It 
is suggestive that risk factors are genetically related. Further study will reveal 
new insight into the underlying shared pathogenic mechanisms of complex 
common disease. 
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Genome-wide Association Studies 
Genome-wide association studies, or GWAS, are a relatively new 
phenomena based on the rapid progression of technology. In the past three 
years, GWAS assaying hundreds of thousands of SNPs have identified hundreds 
of associations of common genetic variants, many of which are associated with 
CHD (Human Genome Project Information, 2008; Heng, 2008). There are 
several advantages of GWAS over linkage studies, including the ability to 
genotype large number of SNPs (Human Genome Project Information, 2008). 
Studies have progressed from assaying fewer than 100,000 SNPs to more than 1 
million, and sample sizes have increased dramatically. An additional advantage 
is that you do not need to have multiple affected family members for genome-
wide association studies. You can use large case-control samples of unrelated 
subjects for better statistical power. Also, genome-wide association provides a 
high level of quality control and replication across experiments (Human Genome 
Project Information, 2008). A summary of landmark GWASs are presented here 
(see Table 2). 
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Table 2 
 
Summary of Landmark Genome-wide Association Studies for Coronary 
 Heart Disease 
Author Year Study 
Population 
N Mean 
Age 
Primary Loci Phenotype 
Ozaki 2002 Japanese 94 64 6p21 
 
MI 
Shiffmann 2008 American 4522 73 LPA- 6q26 
VAMP8- 
2p12-p11.2 
TAS2R50- 
12p13.2 
KIF6- 6p21.2 
 
MI 
Chen 2009 American 332 59 9p21 
 
CHD 
Large 
Scale 
2009 European 22,755 58 9p21 
1p13.3 
2q36.3 
10q11.21 
 
CHD & MI 
Kathiresan 2009 International 25,538 46 21q22 
6p24 
2q33 
 
Early onset 
MI 
Erdmann 2009 Northern 
European 
 
19,407 60 3q23.3 Premature 
CHD 
Trégouët 2009 Northern  
European 
8,999 58 6q26-27 CHD 
Note: Abbreviations; MI: myocardial infarction, CHD: coronary heart disease.  
 
Ozaki et al. (2002) published one of the first CHD GWAS in 2002. Ninety-
four Japanese individuals with MI were initially genotyped through genome-wide 
association, suggesting the gene LTA on chromosome 6p21 was associated with 
MI. An additional 1,133 subjects were screened for gene variation in the critical 
region. Two SNPs in the LTA region were shown to affect expression level and 
biologic function of several adhesion-molecules, including ICAM-1, in vascular 
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smooth muscle in a coronary artery. The genotyping covered less than 100,000 
SNPs, which is well below our current standard of at least 250,000 tagging 
SNPs. However, the study reinforces the pro-inflammatory role in CHD (see 
Table 2) (Ozaki et al., 2002). 
Shiffmann et al. (2008) evaluated 4,522 subjects in the Cardiovascular 
Health Study for the presence of 74 SNPs. The SNPS were identified in 
antecedent studies to be associated with MI. Four of the SNPs from genes LPA, 
VAMP8, TAS2R50, and KIF6 were also associated with MI in this study 
(Shiffman et al., 2008).   
Chromosome 9p21 has been the most widely studied risk variant for CHD 
and MI, and is the first confirmed independent genetic risk factor for CHD by 
GWAS  (Samani, 2009; Karvanen, 2009; Meng, 2008; Schunkert, 2008; Samani, 
2007; Chen, 2009; Anderson, 2008; Paynter, 2009). However, there has been no 
evidence of gene-environmental interaction in that 9p21 is not associated with 
traditional risk factors. 9p21 was assessed in one of the largest CHD genetic 
experiments to date (Large Scale Association Analysis of Novel Genetic Loci for 
Coronary Artery Disease, 2009). A total of 22,755 participants were recruited 
from nine European studies. The loci on 9p21 was once again shown to be 
associated with an increased risk of CHD, as were loci on 1p13.3, 1q41, and 
10q-11.21 (Large Scale Association Analysis of Novel Genetic Loci for Coronary 
Artery Disease).  
The Myocardial Genetics Consortium was also a large trial, with a sample 
size of 19,492 (Kathiresan et al., 2009). They evaluated the association of SNPs 
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and copy number variants (CNV) with early-onset MI. Copy number variants are 
differences in DNA structure when compared across genomes (Kathiresan et al., 
2009). Copy number variants may account for variation which has not been 
captured by standard GWAS arrays (Manolio et al., 2009). Variation from CNVs, 
like SNPs, can arise from a combination of rare or common alleles. Interestingly, 
highly penetrant CNVs discovered to date have been rather large, effecting many 
genes (Manolio et al.). Nine SNPs meet genome wide significance. Six had been 
previously identified: 9p21, 1p13, 10q11, 1q41, 19p13, and 1p32, and three were 
newly discovered SNPs: 21q22, 6p24, 2q33 (Kathiresan et al.). This study found 
significant results from genetic mapping of the SNP analysis with a calculated 
risk of early onset MI of 2.8%; however, it did not find an association with 
myocardial risk and CNV (Kathiresan et al.).   
Erdmann et al. (2009) utilized the Myocardial Genetics Consortium 
database to evaluate SNPs that had been previously dismissed due to modest 
effects or low allele frequencies. A three-stage analysis began with genotyping 
1,222 German individuals and 1,298 case-controls. The study findings were 
ultimately replicated in over 25,000 subjects utilizing three databases. Subjects 
were included if they had premature CHD and a positive family history of CHD. 
Genotyping was carried out with an Affyemetrix Genome Wide Human SNP 
Array. The study identified one new CHD risk locus on 3q22.3 (p = 7.44 x 10 -13, 
OR = 1.15, 95% CI = 1.11-1.19) and a suggestive association with a locus on 
12q24.31 (p = 4.81 x 10 -7, OR = 1.08, 95% CI = 1.05 -1.11). The locus on 
12q24.31 is clustered near the coding region of HN1FA and C12of43. These 
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regions are implicated in T2DM in the young, as well as with increased CRP and 
LDL levels (Erdmann et al.).   
A similar study design, which ultimately included 6,100 cases and 5,600 
controls, was utilized to identify gene cluster at the 6q26-q27 locus (Tregouet et 
al., 2009). This locus encompasses the SLC22A3-LPAL2-LPA genes, which 
have a strong susceptibility locus for CHD. The identified locus partly overlaps 
the gene which encodes for apolipoprotein(a) (Tregouet). 
Genome wide association scans have continued to demonstrate a vast 
number of susceptibility regions for CHD, most with a low penetrance 
(Torkamani, Topol, & Schork, 2008). This suggests that CHD is modulated by a 
large number of low-risk genetic factors. Coronary heart disease has a complex 
pathogenesis, as demonstrated by the associated risk factors and genetic 
overlap. FAM5C has emerged as a novel gene of interest. FAM5C demonstrates 
the concept of genetic overlap, in as much as it has been associated with MI, the 
inflammatory biomarker MCP-1 (Dupuis et al., 2005) and MetS (Langefeld et al., 
2004).   
FAM5C 
The GENECARD study, involving six international centers, performed a 
genome-wide scan on families in which two or more siblings had documented 
early onset CHD (Hauser et al., 2004). The study included 493 affected sibling 
pairs, of which 71% were male. Early onset CHD was defined as 51 years of age 
for men and 56 years old for women. The sample was prospectively stratified into 
three phenotypic subsets. The first included ACS families, which were defined as 
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the diagnosis of an MI or unstable angina in at least two affected siblings. The 
second was the absence of T2DM in all affected siblings, and the third was 
atherogenic dyslipidemia in any one sibling. Genotypes were analyzed for 395 
microsatellite markers. Two regions, 3q13 and 1q25-31, met the criteria for 
genome-wide significance. A priori stratification by sibling pairs for ACS revealed 
a well-defined linkage peak on 1q25-31 (n = 228 families, LOD = 2.17, at peak 
microsatellite marker D1S1589/D1S518) (Hauser et al., 2004).  
Three separate studies have identified genetic linkage to the same region 
on chromosome 1q. The Framingham Heart Study (Dupuis et al., 2005) identified 
a linkage peak for the inflammatory biomarker monocyte chemoattractant protein 
1 (MCP-1) (LOD = 4.27, at peak microsatellite marker D1S1589). This correlated 
exactly with the linkage peak (LOD = 2.59, D1S1589/D1S518) for MetS in the 
Insulin Resistance Atherosclerosis Study (Mercuro et al.) Family Study 
(Langefeld et al., 2004), and the Genetics for Early Onset Cardiovascular 
Disease Study (GENECARD) identified modest linkage to ACS (LOD = 2.17, 
D1S1589/D1S518) (Connelly et al., 2008; Hauser, 2004). A SNP found within the 
first intron of the tumor necrosis factor superfamily 4 gene (TNFSF4), 
(rs3850641) has also been found to reside within the chromosome 1q linkage 
peak and has been strongly associated with MetS and MI in two independent 
populations (Wang et al., 2005). However, it was not linked in the GENECARD 
samples (Connelly et al.; Wang et al.). The precursor for CRP has also been 
linked to the 1q region (Dupuis et al.; Benjamin et al., 2007). This genetic overlap 
gives strong support to a CHD susceptibility gene in this region. 
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The Framingham Heart Study Offspring cohort was used to perform a 
genome scan of inflammatory biomarkers (Dupuis et al., 2005). A total of 3304 
participants with documented CVD were included. Cardiovascular disease was 
defined by the presence of CHD, stroke, claudication, or congestive heart failure. 
Four biomarkers of vascular inflammation were measured using enzyme-linked 
immunosorbent assays. The biomarkers included CRP, IL-6, MCP-1, and ICAM-
1. A total of 330 families (1702 individuals) were genotyped using 401 
polymorphic markers. An additional 506 individuals without biomarker data were 
genotyped to include in the linkage analysis to increase the number of shared 
alleles from common ancestors. After log transforming and adjusting for 
covariates, the heritability estimates were the highest for MCP-1 at 44%, followed 
by ICAM-1 at 30.4%, and CRP at 28.2%. IL-6 had the lowest heritability at 
13.7%. The maximum LOD score of 4.27 was achieved for MCP-1 on 
chromosome 1q25.1 at 186 cM marker D1S1589 (nominal p = .000004, genome-
wide p = .005). This study found that inflammatory biomarker levels were 
heritable phenotypes and supports the hypothesis that some chromosome 
regions may harbor inflammation susceptibility genes (Dupuis et al., 2005).   
The IRAS Study also found linkage on at 1q23-q31 at marker D1S1589 
(Langefeld et al., 2004). The IRAS study was designed to map genes that 
predispose to insulin resistance, cardiovascular disease, and obesity. Thirty-five 
Hispanic pedigrees (216 individuals) were recruited from the San Antonio, Texas 
(SA) and San Luis Valley, Colorado (SLV). The overall presence of MetS in the 
sample was 35% as defined by ATP III criteria. A 10 cM genome scan was 
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conducted on all participants. Nonparametric linkage analysis revealed strong 
evidence for linkage with MetS to chromosome 1q between markers D1S1589 
and D1S1518 in the San Antonio cohort with a LOD score of 2.59 (Langefeld et 
al.). These results contribute to the growing evidence of an inflammatory locus on 
1q. Linkage of T2DM to the 1q21-31 regions has previously been reported in 
Pima Indians, African Americans, French, European-Caucasian, Hispanic 
Americans, Utah Caucasians, Amish, and Chinese populations (Hanson et al., 
1998; Elbein, Hoffman, Teng, Leppert, & Hasstedt, 1999; Vionnet et al., 2000; 
Wiltshire et al., 2001; Hsueh et al., 2003; Meigs, Panhuysen, Myers, Wilson, & 
Cupples, 2002). Within these data sets, there has been significant 
correspondence between linkage in the 1q region (Wiltshire et al., 2001). The 
U.K., Utah, French, and Pima populations all fall within a 30 cM interval on 1q 
(Vionnet et al., 2000; Hanson et al., 1998; Elbein, Hoffman, Teng, Leppert, & 
Hasstedt, 1999). This is consistent with a common susceptibility locus and 
coincides with the leakage peak for FAM5C on 1q25-31 (LOD 2.17, at peak 
microsatellite marker D1S1589/D1S518) (Connelly et al., 2008). Replication of 
linkage results from additional populations will provide vital confirmation of the 
original findings. 
Wang et al. (2005) identified a quantitative trait locus on mouse 
chromosome 1 that encompasses 11 known genes. This is a homologous region 
between 1q24.3 and 1q25.1, which includes TNFSF4 and resides within the 
FAM5C linkage peak. Polymorphisms in TNFSF4 are associated with the risk of 
MI and severity of atherosclerotic disease. Wang et al. demonstrated that mice 
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with the targeted mutations of TNFSF4 had significantly (p < .05) smaller 
atherosclerotic lesions than the control mice. Alternatively, mice over-expressing 
TNFSF4 had significantly (p < .05) larger atherosclerotic lesions than controls. 
Wang’s findings were confirmed in two independent human populations. The first 
study was the Stockholm Coronary Artery Risk Factor Project, which genotyped 
a total of 383 subjects with MI before the age of 60 and the Stockholm 
Epidemiology Heart Program. The Stockholm Epidemiology Heart Program 
consisted of 2,246 men and women who were treated for a first-time MI and 
3,206 controls (Leander et al., 2007). In both populations the less common allele 
of SNP (rs3850641) in TNFSF4 was significantly (p < .05) more frequent in 
individuals with MI than in controls. Wang et al. concluded that TNFSF4 
increased the risk of MI in humans.  
The GENECARD ACS sibling cohort was correlated with the 
Catheterization Genetics (CATHGEN) MI case-control dataset (Connelly et al., 
2008). CATHGEN participants were recruited through the catheterization 
laboratories at Duke University Hospital. Controls and cases were chosen on the 
basis of extent of coronary artery disease (CAD) on the CAD index. The CAD 
index is a numerical summary of angiographic CAD, which incorporates the 
extent and distribution of the disease. The sample consisted of 368 MI cases and 
289 controls; 83% were male (Connelly et al., 2008). 
 A peak-wide association screen was performed with 457 SNPs to 
evaluate for polymorphisms within FAM5C and determine if there was an 
association with MI (Connelly et al., 2008). This correlates to a linkage peak for 
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ACS on chromosome 1q. One SNP (rs1891586) from the peak-wide screen 
showed both linkage and association in the ACS sample. Additional fine mapping 
was performed 15 kilobases upstream and 5 kilobases downstream from the 
gene, using 67 haplotype tagging SNPs identified by HapMap data. Only 48 
SNPs had allele frequencies > 5%. Sixteen of the SNPs showed linkage and/or 
association, with three SNPs partially accounting for the linkage signal on 
chromosome 1 by LAMP analysis (Connelly et al., 2008). LAMP analysis uses a 
maximum likelihood model to provide information on genetic linkage and 
association from samples of unrelated individuals, sib pairs, trios and larger 
pedigrees (Li et al., 2006). In the CATHGEN sample, 12 of the 16 SNPs were 
significantly associated with MI. However, only one of the SNPs in the 
CATHGEN sample was associated with GENECARD (Connelly et al., 2008). 
Ultimately, only one SNP rs10920501 (LOD = 2.98, p = 0.018), displayed linkage 
and association in both samples.  
When the CATHGEN MI sample was stratified by age of onset, there was 
an earlier age of onset (< 55 years) for the subjects with the wild type A allele (J. 
Connelly, personal communication, May, 9, 2010). This is consistent with 
identification of the same allele in the GENECARD young affected sample. Gene 
expression of FAM5C SNP rs10920501 was evaluated with 83 aortic tissue 
samples, of which 58 were unique (Connelly et al., 2008). Human aorta samples 
were collected from heart transplant donors. Gene expression data showed a 
decrease in the level of FAM5C expression with the presence of the variant T 
allele, suggesting that higher levels of FAM5C may lead to MI. The authors did 
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not age-stratify the gene expression sample because it was too small (n = 58) (J. 
Connelly, personal communication, May, 9, 2010).  
FAM5C, also known as BRINP3, was initially identified in the mouse brain 
as a gene that is induced by bone morphogenic protein and retinoic acid 
signaling (Kawano et al., 2004). Bone morphogenic protein and retinoic acid play 
an important role in the neuronal differentiation of the peripheral nervous system 
(Kawano et al., 2004). A study by Shorts-Cary et al. (2007) found FAM5C was 
over-expressed in pituitary tumors. Subcellular localization studies showed that 
FAM5C was targeted to the mitochondria. Thus, FAM5C is a mitochondrially 
localized protein and its action can lead to proliferation, migration, and invasion 
of nontumorogenic pituitary cells (Shorts-Cary et al., 2007). Through multiple 
signaling cascades, mitochondria play a vital role in the cell cycle, development, 
and ultimately cell death (McBride, Neuspiel, & Wasiak, 2006). Mitochondrial-
controlled apoptosis is considered a crucial event in many disease processes 
(Rustin, 2002). Localization of FAM5C to the mitochondria served as the basis 
for Connelly et al.’s (2008) hypothesis. They propose that FAM5C levels could 
play a role in the initiation of smooth muscle cell proliferation and migration 
and/or in the disintegration of smooth muscle cells in the fibrous cap. FAM5C 
expression has been demonstrated in both proliferating aortic smooth muscle 
cells and human endothelial cells. It was shown that FAM5C transcript levels 
decrease with increasing passage of aortic smooth muscle cell, suggesting that 
the level of gene expression may play a role in proliferation and senescence of 
this cell type (Connelly et al.).  
  37 
Summary 
Through overlap of multiple genetic screens in independent data sets, a 
well-defined linkage peak on chromosome 1 has emerged as a susceptibility 
region for CHD. A single SNP, rs10920501, can partially account for the linkage 
peak. FAM5C is a localized to the mitochondria and expressed in the human 
aorta. The relationship between inflammatory biomarkers, MetS, MI, and FAM5C 
remains to be clarified. It is well accepted that inflammation is at the root of these 
pathologies, but the mechanisms are unclear. Inflammation plays an important 
role in MetS, and individuals with MetS are at higher risk for CHD. Additionally, 
vascular smooth muscle pathophysiology is related to inflammation which could 
explain the MCP-1 QTL linkage (Connelly et al., 2008). Further research is 
needed to clarify the relationships.    
Gaps in Knowledge 
Despite recent success in GWAS studies in identifying genes that are 
associated with CHD, a large proportion of the genetic and metabolic 
components of CHD remain unattributed. Many of the variants that have been 
identified are not functional (Bilder et al., 2009). Therefore, the roles of most 
genetic variants in the pathology of disease have yet to be discovered.    
The role of the gene-gender interaction in the etiology of common 
diseases is becoming more apparent. Most GWAS studies to date have been 
performed on combined analysis from both genders, using gender as a covariate 
(Silander et al., 2008). In a case-control Japanese study of MI, results were 
analyzed separately by gender, revealing that the variants differed for men and 
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women (Yamada, 2002). A similar result was produced when analyzing MetS 
(McCarthy, 2007). Further study of the gene-gender interaction and its underlying 
basis is necessary to clarify inter-individual variation.       
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Chapter Three 
 
Methods 
 
Introduction 
 
Chapter three presents the methodology of the study. This section 
includes a description of the study design, the sample, setting, data collection, 
measures, and the data analysis plan. Limitations are reviewed, as well as the 
steps taken for the protection of human subjects and plan for dissemination of 
the study findings.  
Design 
This study was an exploratory, descriptive pilot gene association study. 
Data from a subset of patients enrolled in cardiac rehabilitation program tailored 
for women with CHD was utilized for the study (Beckie et al., 2009). The parent 
study was funded by the National Institute of Nursing Research (grant number 
R01NR007678). In the parent study, women were randomized to a traditional 
cardiac rehabilitation program (CR) or a women’s-only behaviorally enhanced, 
staged-matched intervention. The experimental intervention includes 10 psycho-
educational sessions with motivational interviewing, social support, and 36 ECG-
monitored exercise sessions over 12 weeks. The institutional review boards of 
the participating hospital and university approved the parent study. The subjects 
from the parent study consented for the use of all data, their genetic material, 
and biological samples in further studies of CHD. Therefore, there was no 
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additional recruitment or consent required for the study. This was a secondary 
analysis of the data previously collected. 
Sample  
Recruitment for the parent study was generated primarily through an 
automatic hospital discharge protocol, although advertising was also utilized 
(Beckie et al., 2009). The inclusion criteria for the parent study included women 
over the age of 21 years, with the diagnosis of a MI, unstable angina, or coronary 
revascularization within the last year. All participants were oriented to person, 
place and time, able to read, write, and speak English, and were willing to 
participate (Beckie, 2006; Beckie, Fletcher, Beckstead, Schocken, & Evans, 
2008). Approximately 250 women were enrolled in the parent study. High 
sensitivity-CRP, IL-6, TNF-α, and ICAM-1 have been measured at three time 
points (baseline, post-intervention, and at a six month follow-up) in the parent 
study. Ninety-one subjects from the parent study with stored blood samples were 
included in the current gene association study (Beckie et al., 2009). 
Setting 
The study was completed in the University of South Florida, College of 
Nursing Biobehavioral Laboratory. The clinical data collection and interventions 
were conducted at the study hospital. DNA purification and genotyping was 
performed in the Biobehavioral Laboratory at the College of Nursing.  
Data Collection 
Demographic and clinical information were collected in the parent study by 
blinded research assistants at three time points including baseline, 13 weeks, 
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and 37 weeks. Data were stored in a locked cabinet and on password-protected 
computers in the office of the Principal Investigator. Data used in the study were 
extracted by the Principal Investigator of the parent study. To assure subject 
confidentiality, all identifiers were removed from the data. A non-identifying study 
number was given to link the parent study data and biological samples for the 
study. 
Measures  
 Clinical Characteristics. Baseline assessments were collected on all 
subjects in the parent study, which included risk factors for CHD, 
anthropomorphic measures, and fasting lipid and glucose measurements 
(Beckie, Fletcher, Beckstead, Schocken, & Evans, 2008). Blood pressure (BP) 
was measured with a calibrated Accutor plus oscillometric BP monitor 
(Datascope, Mahwah, New Jersey) according to established guidelines. Body 
mass index was calculated as weight (kg)/ height (m²). Twelve hour fasting lipid 
and glucose measurements were obtained utilizing the Cholestech LDX system 
(Beckie et al., 2008). Metabolic syndrome was defined by the revised NCEP ATP 
III criteria (Grundy et al., 2006). 
Inflammatory Biomarkers. Blood samples were obtained in all patients 
prior to completing the baseline assessments for the parent study. The collection 
was performed between the hours of 0700am and 1200pm, after a 12 hour fast. 
A total of 5.0 ml of blood was collected via venipucture into a vacutainer tube. 
The samples were centrifuged at 3500 rpm at 0˚ C; serum samples were then 
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stored in 1.0 mL eppendorf tubes and immediately placed at -80˚C until further 
analysis.  
High sensitivity-CRP, IL-6, TNF-α, and ICAM-1 were measured using the 
Luminex 200 IS system. The Luminex system is a laser-based fluorescent 
analytical system, which is used in conjunction with LINCOplex Bio-assays 
(LINCO Research St. Charles, Missouri). All assays were analyzed per 
manufacturers’ protocol. Duplicates were run for all samples and concentrations 
were analyzed using a 5-parameter logistic curve-fitting method. Measures that 
were obtained with less than the minimum detectable concentration were 
arbitrarily set equal to half the detection level. Serum hs-CRP was measured in a 
LINCOplex Human Cardiovascular Disease Panel 2. The sensitivity or minimum 
detectable concentration for this assay is 6 pg/mL, the intra-assay precision was 
8.0%, inter-assay 17.5% (Millpore Technical Publications, 2005b). Interleukin six 
and TNF-α were measured using the Human Cytokine LINCOplex kit. 
Sensitivities for these assays are 0.22 and 0.79 pg/mL, respectively. Intra-assay 
precision was 1.7%, inter-assay precision is < 10% (Millpore Technical 
Publication, 2006). Intercellular adhesion molecule-1 was measured using the 
Human Sepsis/Apoptosis LINCOplex kit per manufacturers’ protocol. This assay 
has a sensitivity of 30 pg/mL with intra-assay precision of 5.5%, and inter-assay 
of 8.7% (Millpore Technical Publication, 2005a). 
DNA Specimens. DNA was isolated and purified from the stored samples. 
The samples were centrifuged for 30 minutes at 4°C to pellet the cells. They 
were resuspended in 100 uL of phosphate buffered saline for DNA extraction. 
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The basic steps of DNA isolation are disruption of the cellular structure to create 
a lysate, separation of the soluble DNA from the cellular debris and other 
insoluble debris, and purification of the DNA from soluble proteins and other 
nucleic acids. A QIAmp DNA Mini Kit was selected for this process (Qiagen, 
Germantown, MD). It has been designed for use with human blood samples 
through the use of spin columns (Quigen Sample and Assay Technologies, 2003-
2009). The cellular structures are enzymatically lysed. DNA binds to the QIAmp 
silica-gel membrane while debris passes through. Debris is completely removed 
in two wash steps, leaving pure DNA to be eluted in buffer (Qiaqen).   
Extraction and Genotyping. Custom Applied Biosystems TaqMan assays 
were used to perform polymerase chain reaction (PCR) for the FAM5C SNP 
(rs10920501). The TaqMan assays were used to perform allelic discrimination 
between the A and T alleles, which have been shown to have a transversion 
substitution on the (rs10920501) SNP (Connelly et al., 2008). Assays for this 
SNP were obtained from the manufacturer (Applied Biosystems, Foster City, 
CA). Different from conventional PCR, TaqMan PCR utilizes a reporter and a 
quencher that recognizes a specific allele of a SNP. The DNA polymerase 
cleaves only probes that are hybridized to the target. Cleavage separates the 
reporter dye from the quencher dye resulting in increased fluorescence by the 
reporter. The increase in fluorescence occurs only if the target sequence is 
complementary to the probe and is amplified during PCR. Each sample required 
the following components: 2.5 uL genomic DNA, 12.5 uL Custom TaqMan SNP 
genotyping Master Mix (Applied Biosystems, Foster City, CA), 1.25 uL of 20x 
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TaqMan assay, and 8.75 uL DNAse free water for a total sample volume of 25 
uL. Reactions were performed in 96 well plates in duplicate using a Bio-Rad CFX 
PCR Detection System (Bio-Rad, Hercules, CA). PCR cycling conditions followed 
the standard TaqMan protocol: Step 1: 95˚C for 10 minutes, Step 2: denaturing at 
40 cycles of 92˚C for 15 seconds, Step 3: 60˚C for 1 minute (Applied Biosystems, 
2006). Analysis was conducted by BioRad CFX Manager Software version 1.5 
(BioRad Laboratories, 2008). 
Data Analysis 
Data were analyzed using SPSS version 18 for Windows (SPSS Inc., 
Chicago, Ill.). Initially data were screened for missing data, outliers, and possible 
confounding factors and to assess whether underlying statistical assumptions for 
the planned analysis were satisfied. There were no missing data. Descriptive 
statistics were used to describe study participants. The significance level was set 
at α = .05. 
Aim One 
Describe the distribution of the genotype in the FAM5C SNP (rs10920501) 
in a cohort of women with documented CHD.  
Frequency counts and percentages were used to describe the frequency 
distribution for the variant SNP. Percentages provide the proportion of valid 
observations found in each of the genotype groups. The SNP has three possible 
genotypes; the homozygous wild type (AA), heterozygous (AT), and the 
homozygous variant (TT). Genotype distributions and allele frequencies are 
reported.  
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Aim Two 
Investigate the associations between the variability in the genotype in the 
FAM5C SNP (rs10920501), MetS, and inflammatory biomarkers among 
women with documented CHD. 
A chi square test was performed to measure the association between 
genotype and MetS. Separate one-way analyses of variance (ANOVA) were then 
performed on the log (base-10) transformed values of hs-CRP, ICAM-1, IL-6, and 
TNF-α from the parent study by genotype. The null hypothesis stated the means 
of the biomarkers were the same for each genotype group. The results are 
reported as an F test. If the obtained F exceeds the critical F, the null hypothesis 
is rejected. The effect size is reported as an eta squared.    
Aim Three 
Evaluate if the FAM5C SNP (rs10920501) is associated with early onset 
CHD in women.  
An ANOVA was used to compare the differences between women with 
early onset CHD and those who manifested the disease later in life. Early onset 
CHD for women has been previously defined by Hauser et al. (2004) as 
occurring at or before the age of 55. Therefore, the age variable was 
dichotomized to two levels, women age < 55 and age > 55. Descriptive statistics 
were used to describe this subset of study participants. There are three levels of 
genotyping. The null hypothesis stated that the mean age of CHD onset is equal 
across all genotypes. The results are reported as an F test and the effect size is 
reported as an eta squared.    
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A supplemental analysis was performed to determine if there was an 
association between genotype and age of onset of CHD in women who had an 
MI. Myocardial infarction was defined as any documented MI in the medical 
record. Some women had more than one MI prior to study enrollment. This 
criterion was established to minimize phenotypic heterogeneity. A one-way 
ANOVA was used to evaluate three levels of genotype and to determine whether 
there was a significant relationship between genotype and age of onset of CHD 
in women who had an MI. A linear regression model was used to assess the 
potential factors that might predict age of onset. The dependent variable was age 
of onset of disease as first documented in the medical record. The independent 
variable was SNP rs10920501.  
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Chapter Four  
 
Results 
 
Introduction 
 
The purpose of this study was to explore the presence of the variant allele 
in the FAM5C gene (rs10920501) in a cohort of women with documented CHD, 
to assess the relationship between FAM5C, MetS, and inflammatory markers, 
and to evaluate if FAM5C variability has predictive value for identifying women 
with early onset CHD. Chapter four presents the baseline characteristics of the 
samples and results of the current study. The baseline data included the clinical 
characteristics, diagnostic criteria for inclusion in the parent study, co-morbidities, 
and medications that the subjects were on at the time of enrollment to the parent 
study. The results of the study are presented by aim.  
Baseline Characteristics 
Ninety-one women from the parent study had inflammatory biomarker data 
and stored samples available for examination in the current study. Demographic 
characteristics from the subset of women are presented in Table 3, with 
comparative data from the GENECARD sample (Hauser et al., 2004). The 
women in the current study had a mean age of 61.6 years (SD = 10.2), with a 
range of 42 to 82 years. The majority of the women were white (61.5%).  
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The traditional risk factors for CHD are presented in Table 4. Fifty-six 
percent of the study participants had a history of smoking, with a mean 14.1 + 19 
pack years. Nearly fifty percent of the women had a self-reported family history of 
heart disease, and the majority of the women were diagnosed as hypertensive 
(82.4%), although most were on antihypertensives at the time of enrollment to 
the parent study. The mean total cholesterol at baseline was 162 + 38 mg/dL, the 
mean HDL-C was 43.4 + 12.5 mg/dL, the mean baseline LDL-C was 93 + 33.7 
mg/dL, with a range from 37-206 mg/dL. Triglycerides also had a wide range 
from 45- 358 mg/dL, with a mean value of 132 mg/dL. Women in the current 
study had a mean BMI of 32.4 + 7.3 kg/m². Thirty-seven percent of the women in 
the current study were diabetic and 36% met the revised  ATP III criteria for MetS 
(Grundy et al., 2006).   
Table 3  
 
Demographic Characteristics of the Sample Compared to GENECARD 
Sample 
Variable CURRENT 
 
n = 91 
 
n (%) 
GENECARD* 
 
n = 422 
 
n (%) 
Age  mean (SD) 61.6 (10.2) 44.2 (5.8) 
Women 91 (100.0) 124 (29.4) 
Race/Ethnicity   
 Caucasian (Non-Hispanic) 56 (61.5) 392 (92.9)  
 African American 16 (18.0) 9 (2.1) 
 Hispanic 19 (22.0) 0 
*(Hauser et al., 2004)   
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Risk Factors of the Current Study Sample Compared to GENECARD Sample 
Variable 
 
CURRENT 
 
n = 91 
 
n (%) 
GENECARD* 
 
n = 422 
 
n (%) 
Risk Factors   
Diabetes 34 (37.4) 94 (22.3) 
Metabolic syndrome 33 (36.3) Unreported 
History of smoking 51 (56.0) 329 (78.0) 
Hypertension 72 (82.4) 240 (56.9)  
Familial heart disease 43 (47.3) 422 (100.0) 
Total cholesterol, mg/dL 162 (38.0) 239 (64.8) 
HDL-C, mg/dL 43.4 (12.5) 38.7 (16.3) 
LDL-C, mg/dL 93 (33.7) 146.1 (54.3) 
Triglycerides, mg/dL 132 (64.6) 230.1 (138.8) 
Body mass index, kg/m² 
 
Waist circumference, cm 
32.4 (7.3) 
 
100.9 (15.2) 
29.9 (5.8) 
 
Unreported 
Note: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol. Continuous variables are displayed as mean 
(SD) and categorical variables are displayed as n (%). *(Hauser et al., 
2004). 
 
 
Women qualified for inclusion in the parent study based on the diagnosis 
of an acute MI (29.7%), unstable angina (12.1%), coronary artery bypass graft 
(CABG) surgery (31.9%), or percutaneous coronary intervention (PCI) (48.4%) 
within the last year (see Table 5). Medical record review also revealed a previous 
 
Table 4.  
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history of MI in 17.6% of the women, stable angina in 13.2%, CABG surgery in 
7.7%, and previous PCI in 11%. At the time of enrollment, 78% of the women 
were on beta-blockers, 32% were on angiotensin-converting enzyme inhibitors, 
88% were taking aspirin, 67% taking clopidogrel, 93% lipid-lowering agents, 26% 
were taking nonsteroidal anti-inflammatory agents, and 6.6% were on estrogen 
replacement.  
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Eligibility Criteria, Co-Morbidities, and Medications of Study Sample 
Variable n = 91 
 
n (%) 
Eligibility for the Parent Study 
 
Acute myocardial infarction 
 
Unstable angina 
 
Coronary artery bypass graft surgery 
 
Percutaneous coronary intervention 
 
Co-Morbidities 
 
Previous myocardial infarction 
 
Previous angina 
 
Previous coronary bypass graft surgery 
 
Previous percutaneous intervention   
 
Medications  
 
Beta-blocker 
 
Angiotension converting enzyme inhibitor 
 
Aspirin 
 
Clopidogrel 
 
Lipid lowering agents 
 
Nonsteroidal anti-inflammatory agents 
 
Estrogen replacement 
 
 
27 (29.7) 
 
11 (12.1) 
 
29 (31.9) 
 
44 (48.4) 
 
 
 
16 (17.6) 
 
12 (13.2) 
 
7 (7.7) 
 
10 (11.0) 
 
 
 
71 (78.0) 
 
29 (31.9) 
 
80 (87.9) 
 
61 (67.0) 
 
85 (93.4) 
 
24 (26.0) 
 
6 (6.6) 
 
 
 
Table 5  
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Results by Aim 
Aim One- Distribution of the Genotype 
The first aim was to describe the distribution of the genotype in the 
FAM5C SNP (rs10920501) in a cohort of women with documented CHD. The 
SNP genotyping distribution included the homozygous wild type (AA), the 
homozygous variant (TT), and heterozygous (AT). Frequencies and percentages 
of the genotyping in the current study and those in HapMap distributions are 
presented in Table 6 (International HapMap Project, 2008).   
Table 6  
Distribution of the FAM5C SNP (rs10920501) by Genotype 
Genotype 
 
Current Sample (n = 91)     
 
 n (%) 
HapMap* 
 
Percentage 
Homozygous wild (AA) 61 (67.0) 65% 
 
Homozygous variant (TT) 
 
4 (4.4) 
 
5% 
 
Heterozygous (AT) 
 
26 (28.6) 
 
30% 
* International HapMap Project, 2008 
 
Important implications of the HWE equilibrium include allele frequencies 
remain constant across generations, and that for rare alleles, the frequency of 
the heterozygote far exceeds the frequency of the rare homozygote (Rodriguez, 
Guant, & Day, 2009). This distribution was tested for deviation from the Hardy-
Weinberg equilibrium (HWE). The null hypothesis was that the sample was in 
HWE. The SNP was found to be in HWE (χ² = 0.32, df = 1, p = .57); therefore, 
the null hypothesis was not rejected.  
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Aim Two- Association Between Genotype, Metabolic Syndrome, and 
Inflammatory Biomarkers 
Aim two investigated the associations between the variability in the 
genotype in the FAM5C SNP (rs10920501), MetS, and inflammatory biomarkers 
among women with documented CHD. A chi square test was performed to 
determine if there was a significant relationship between subjects with MetS and 
without MetS at baseline, and whether this was related to genotype (See Figure 
2). Of the total sample, thirty-three subjects (36%) had MetS at baseline. The 
results indicated that MetS was not related to FAM5C SNP rs10920501 (χ² = .36, 
df = 2, p =.84). Supplemental analysis also examined the relationship between 
genotype and diabetes and found no relationship (χ² = .28, df = 2, p =.87).  
Figure 2. Relationship Between Baseline Metabolic Syndrome and Genotype 
0 10 20 30 40 50 60 70 80 
No MetS n=58 
MetS n=33 
Frequency (%) 
Homozygous variant TT 
Heterozygous AT 
Homozygous wild AA 
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Separate one-way analyses of variance (ANOVA) were performed on the 
log (base-10) transformed means of hs-CRP, ICAM-1, IL-6, and TNF-α from the 
parent study by genotype (Table 7). The results suggested there was no 
relationship between genotype of FAM5C SNP rs10920501 and any 
inflammatory markers. The effect sizes (eta²) indicate that there was no 
systematic relationship between inflammatory biomarkers and FAM5C SNP 
rs10920501 in this study. 
 
Relationship Between Inflammatory Biomarkers and FAM5C SNP rs10920501 
 Variable AA 
 
n = 61 
AT 
 
n = 26 
TT 
 
n = 4 
F 
 
(2,88) 
p η² 
hs-CRP mg/L  
 
ICAM-1 pg/mL 
 
IL-6 pg/mL 
 
TNF-α pg/mL 
1.32 (.49) 
 
2.26 (.21) 
 
.84 (.45) 
 
.81 (.33) 
1.37 (.56) 
 
2.28 (.29) 
 
1.00 (.60) 
 
.88 (.43) 
1.31 (.61) 
 
2.28 (.29) 
 
.80 (.33) 
 
.88 (.32)  
.13 
 
.04 
 
.94 
 
.42 
.88 
 
.93 
 
.40 
 
.66 
.00 
 
.00 
 
.02 
 
.01 
Note: Data are presented as means (SD). Inflammatory biomarkers are 
presented as log transformed data. Abbreviations: AA, homozygous wild AA; AT, 
heterozygous AT; TT, homozygous variant TT; hs-CRP, high-sensitivity C-
reactive protein; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; 
TNF-α, tumor necrosis factor-α.  
   
 
Aim Three- The Relationship Between FAM5C and Early Onset CHD 
Aim three evaluated if the FAM5C SNP (rs10920501) was associated with 
early onset CHD in women. Early onset CHD was dichotomized by a mean age 
of < 55 (n = 35) and a mean age of > 55 (n = 56), which is consistent with the 
genetics literature. A one-way ANOVA was used to evaluate three levels of 
Table 7  
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genotype and to determine whether there was a significant relationship with early 
onset CHD in women. The null hypothesis stated that the mean age of CHD 
onset is equal across all genotypes. The mean age of women with the onset of 
CHD at or before the age of 55 was 51.8 years (SD 6.6). The mean age of 
women with onset of CHD after 55 was 67.7 years (SD 6.6). When age of onset 
of CHD was assessed by genotype (Table 8), women with the homozygous 
variant (TT) genotype on average had a later onset of CHD, with a mean age of 
64.5 years (n = 4). However, the ANOVA failed to reach statistical significance (F 
(2, 88) = .96, p = .39), and the null hypothesis was not rejected.  
 
Age of Onset of Coronary Heart Disease by Genotype 
Independent Variable N Mean (SD)    Minimum - Maximum 
Homozygous wild (AA) 
 
Heterozygous (AT) 
 
Homozygous variant (TT) 
61 
 
26 
 
4 
58.5 (11.1) 
 
61.0 (10.0) 
 
64.5 (9.3) 
40 - 82 
 
36 - 74 
 
55 -73 
Note: Minimum, maximum, and mean presented in years. SD, standard 
deviation.  
 
 
Clinical characteristics of the sample were examined stratified by age of 
CHD (< 55 years and > 55 years) (see Table 9). Women diagnosed at 55 years 
or younger were less likely to be diabetic than those diagnosed later in life (χ² = 
4.23, df = 1, p = .04). The early onset group were less likely to meet the criteria 
for MetS than the late onset group (χ² = 91.00, df = 1, p = <.01), and were more 
likely to have a previous history of ever smoking (χ² = 13.79, df = 1, p = <.01). 
Women in the early onset group were less likely to be hypertensive than the late 
Table 8  
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onset group (χ² = 43.5, df = 1, p = <.01), and were more likely to have a family 
history of heart disease than late onset group (χ² = 7.69, df = 1, p = <.01). There 
were no significant differences in the lipid profiles or BMIs between the two 
groups of women.  
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Table 9 
Risk Factors Stratified by Age of Coronary Heart Disease Onset   
Variable 
 
Total Sample 
 
n = 91 
 
n (%) 
CHD < 55yrs 
 
n = 38 
 
n (%) 
CHD > 55 yrs 
 
n = 53 
 
n (%) 
 
 
 
 
p 
Risk Factors 
 
Diabetes 
 
Metabolic 
syndrome 
 
Smoking 
 
Hypertension 
 
Familial heart 
disease 
 
Total cholesterol, 
mg/dL 
 
HDL-C, mg/dL 
 
LDL-C, mg/dL 
 
Triglycerides, 
mg/dL 
 
Body mass index, 
kg/m² 
 
 
34 (37.4) 
 
33 (36.3) 
 
 
51 (56) 
 
72 (82.4) 
 
43 (47.3) 
 
 
162 (38) 
 
 
43.4 (12.5) 
 
93 (33.7) 
 
132 (64.6) 
 
 
32.4 (7.3) 
 
 
11 (28.9) 
 
13 (34.2) 
 
 
27 (68.4) 
 
29 (76.3) 
 
22 (57.9) 
 
 
161 (39.9) 
 
 
41.5 (10.2) 
 
91.1 (35.0) 
 
140.6 (66) 
 
 
33.8 (8.0) 
 
 
23 (43.4) 
 
20 (37.7) 
 
 
25 (46.2) 
 
46 (86.8) 
 
21 (39.6) 
 
 
162.9 (37.2) 
 
 
44.8 (13.8) 
 
94.2 (32.9) 
 
125.9 (63.4) 
 
 
31.3 (6.8) 
 
 
.04 
 
< .01 
 
 
< .01 
 
< .01 
 
< .01 
 
 
.84 
 
 
.19 
 
.68 
 
.94 
 
 
.17 
Note: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol. Lipid profile and body mass index results are presented as means 
(SD).   
  
 
For those women that experienced an MI (n = 38, 41.8%), a one-way 
ANOVA was conducted to examine the relationship between genotype and age 
of onset. The null hypothesis stated that for women with an MI, the mean age of 
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CHD onset is equal across all genotypes. When the women who ever had an MI 
were assessed by genotype, none had the homozygous variant (TT). This finding 
is consistent with the strong protective effect of the T allele. Women with the 
homozygous (AA) genotype had a mean age of onset at 55.1 (SD 7.7) years, 
compared to a mean age of onset of 61.5 (SD 10.0) years for the heterozygous 
(AT) genotype, which was significant (F (1, 36) = 4.61, p = .038). The 
homozygous wild type (AA) genotype represented 71.1% (n = 27) of the women 
who experienced an MI (Table 10). Therefore, the null hypothesis was rejected. 
 
Age of Onset of Coronary Heart Disease by Genotype in Women with a 
History of Myocardial Infarction (n = 38) 
Independent Variable n (%) Mean (SD)    Minimum - Maximum 
Homozygous wild (AA) 
 
Heterozygous (AT) 
27 (71.1) 
 
11 (28.9) 
55.1 (7.7) 
 
61.5 (10.0) 
44 - 70 
 
46 - 74 
Note: Minimum, maximum, and mean presented in years.  
 
A linear regression model was constructed to assess the potential factors 
that might be predictive of the age of onset of an MI (n = 38). A stepwise method 
was used to search candidate variables that the literature has suggested are 
associated with MI. The significant predictors included the homozygous wild type 
AA genotype, smoking, and BMI. Table 11 displays the predictors, the 
unstandardized regression coefficients (B), the standard errors associated with 
the coefficients (SE(B)), the standardized regression coefficients (β), t, and p 
values. R² for regression was significantly different from zero, F (3, 37) = 5.127, p 
Table 10 
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< .01 (Table 11). The adjusted R² of .251 indicates that approximately one 
quarter of the variability of age of onset of MI is predicted by the homozygous 
wild type AA genotype, smoking, and BMI. The R² change indicates that 6.8% of 
the variability in CHD age of onset was unique to genotype. The size and 
direction of the relationships suggest that history of smoking (-.338) is only 
marginally more predictive of age of onset than homozygous wild type AA 
genotype (-.293) and BMI (-.303), as indicated by the squared semi-partial 
correlations. Among women aged 45 to 74 years, women with the homozygous 
wild type AA genotype had an onset of MI 5.6 years earlier than those with the 
heterozygous AT genotype.  
 
Predictors of the Age of Onset of Coronary Heart Disease in Women with a 
 History of Myocardial Infarction 
Predictor 
Variable 
B 
 
SE(B) 
 
β 
 
t P 
Constant 
 
Homozygous wild AA 
 
Smoking 
 
Body mass index 
77.242 
 
-5.601 
 
-.151 
 
-.414 
6.947 
 
2.738 
 
.064 
 
.194 
 
 
-.293 
 
-.338 
 
-.303 
11.119 
 
-2.045 
 
-2.358 
 
-2.130 
.001 
 
.049 
 
.024 
 
.041 
Note:  Adjusted R²= .183 for lifestyle variables, Adjusted R²= .251 for the 3 
predictor model.  
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Chapter Five 
 
Discussion 
 
Introduction 
  
This chapter begins with a discussion of the results by aim. Limitations of the 
current study are reviewed, and the chapter concludes with a summary of 
conclusions and recommendations for future research.  
Discussion of the Results by Aim 
The purpose of aim one was to describe the distribution of the genotype in 
the FAM5C SNP (rs10920501) in a cohort of women with documented CHD. 
Most women were homozygous for the wild type (AA) genotype, with very few 
homozygous for the protective genotype (TT), as one would expect in a sample 
of women with established CHD. The genotype frequencies obtained in this study 
were consistent with those reported by Connelly et al. (2008) and the 
International HapMap Project (2009). Furthermore, there was not a deviation 
from the expected proportions in the population under the Hardy Weinberg 
Equilibrium (Goddard, Ziegler, & Wellek, 2009). The Hardy Weinberg Principle 
states that genotype frequencies will remain constant, or in equilibrium, across 
generations unless certain influences are introduced (Hartl & Jones, 2005). 
Based on this principle, the genotyping results of this study were found to be in 
equilibrium and free from systematic genotyping errors. 
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Clinical characteristics of the current sample were compared to the 
GENECARD study (Hauser et al., 2004). GENECARD was selected for 
comparison because it identified FAM5C as a susceptibility gene for early-onset 
CHD and found a strong association with FAM5C SNP rs10920501 and ACS. 
Family history of CHD was an inclusion criterion for the linkage analysis in 
GENECARD. The women in the current study were unrelated, and less than half 
had a family history of CHD. Overall, the current sample represented an older, 
heavier group that was significantly more hypertensive than those participating in 
GENECARD. There were also fewer MIs in the current study group. In 
GENECARD, more than half of the families had ACS. Diabetes was more 
prevalent in the current study, although smoking was not. An all female cohort 
may explain the discrepancy in smoking rates, as historically women have not 
smoked at the same rates as men (National Health Interview Study, 2008). The 
women in the current study were more ethnically diverse than the subjects in 
GENECARD. Nearly all the subjects in GENECARD were Caucasian, compared 
to slightly over one-half in the current study (Hauser et al.). Lastly, the lipid 
profiles in the current study at first glance appear to be significantly better than 
those in GENECARD. However, this must be placed in the context that 92% of 
the women in the current study were on lipid lowering therapies at the time of 
enrollment. Unfortunately, these data were not reported from GENECARD. 
Discrepancy between rates of traditional risk factors in the current study and 
GENECARD should be put in context with the historical timing of the studies. The 
GENECARD study was completed in 2002, and the current study was completed 
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in 2009 (Hauser et al., 2004). During the period between the two studies, risk 
factor modification evolved considerably (Mosca et al., 2007).  
The purpose of aim two was to investigate the association between 
FAM5C SNP rs10920501, MetS, and inflammatory biomarkers among women 
with documented CHD. The current study did not seek to investigate the 
numerous genes that are reported to be associated with CRP, ICAM-1, IL-6, and 
TNF-α. The investigation of the association was based on the known genetic 
overlap on the same region on chromosome 1q. There have been no previously 
documented associations in the literature between FAM5C SNP rs10920501, 
MetS, and these inflammatory biomarkers. In the current study, there was not 
significant evidence to conclude that MetS or diabetes was related to the FAM5C 
SNP (rs10920501). Additionally, no relationship was found between FAM5C SNP 
rs10920501 and the inflammatory markers investigated. Potential explanations 
for the nonsignificant association between genotypic and phenotypic 
characteristics of MetS, inflammatory biomarkers, and age of onset include the 
multi-factorial nature of CHD influenced by the multiple environmental exposures 
and numerous genetically determined mechanisms underlying disease 
development and progression. Other potential reasons for the inability to 
replicate previous study findings include the influences of race, genetic 
heterogeneity, phenotypic heterogeneity, gene-gene interaction, and low 
statistical power.  
Population stratification occurs when there is marked variation in allele 
frequencies across subgroups of a population, in the context of baseline 
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variability in the disease prevalence within the subgroups (Thomas & Witte, 
2002). This phenomenon has been recognized as a confounding factor in the 
replication of genetic studies. The degree of bias hinges on the heterogeneity of 
allele frequencies and disease risk across and within populations (Thomas & 
Witte). The IRAS study provides a good example of population stratification 
within a Hispanic pedigree (Langefeld et al.). The IRAS study provided evidence 
for linkage on chromosome 1q for MetS, which overlaps with FAM5C. The IRAS 
study was composed of 216 individuals from Hispanic descent from two Hispanic 
pedigrees, San Antonio and San Luis Valley. When the sample was stratified by 
geographic region, there was no evidence linking the subjects from the San Luis 
Valley to chromosome 1q and MetS (Langefeld et al.). This study demonstrates 
that population stratification may have a significant impact on the ability to 
replicate genetic findings. According to Liu et al. (2008), it should not be 
surprising that a significant association identified in one population cannot be 
found in another. The population in the current study was representative of the 
minority composition of the Southeastern United States and was more racially 
diverse than GENECARD (Hauser et al., 2004). Subjects self-identified their 
ethnic background. It has been suggested that current techniques to control for 
race and ethnic background are not always effective, in spite of careful sampling. 
Even when selecting a population based on similar race and shared geography, 
there can be significant differences that effect allele frequencies and the ability to 
replicate association studies.  
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It has been recommended that future studies incorporate genotyping of 
ancestry informative markers (AIMs) to address population stratification. Ancestry 
informative markers are a subset of genetic markers that differ in allele 
frequencies across different populations (Hoggart et al., 2003). It has been 
suggested that by using AIMs, it will be possible to determine a subject’s ethnic 
background from associations on the marker loci and from associations of the 
marker with the trait, even without the benefit of demographic data. Ultimately, 
this should decrease both confounding and selection bias in association studies 
(Hoggart et al, 2003).  
It may be practically impossible to have a sample size large enough to 
overcome between-study heterogeneity (Liu et al., 2008). Small sample and 
effect sizes will contribute to the ability to replicate genetic findings. The vast 
majority of genetic markers discovered in recent association studies have had 
small effect sizes and explain only a fraction of the genetic contribution to 
disease. The sample size needed to overcome small effect sizes is based on the 
heritability of the disease, which includes mean allele frequencies and degree of 
penetrance (Pawitan, Seng, & Magnusson, 2009). For example, given the weak 
effect sizes currently reported for T2DM, approximately 800 variants are required 
to explain a heritability of 40%. It would then take an estimated sample size of 
50,000 cases and 50,000 controls to capture 800 common variants with low 
effect sizes. The sample size to needed to capture rare variants with low effect 
sizes is staggering. It is estimated that at least 125,000 cases and controls are 
necessary to discover approximately 1,400 rare variants (Pawitan, Seng, & 
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Magnusson). The current study had a sample size of 91 women and evaluated a 
single variant. The effect sizes suggest that regardless of sample size, there was 
no relationship between FAM5C SNP rs10920501 and the inflammatory markers 
investigated. However, the ability of a single SNP to make a significant 
contribution to risk prediction of a complex disease remains unlikely. Each SNP 
increases the probability of CHD by a small margin (Schunkert et al., 2010). 
Whether a combination of at-risk SNPs will improve genetic risk prediction 
remains open to debate (Humphries et al., 2004; Janssens, Janicot, Perera, & 
Bakker, 2004).   
Gender-specific risk factors may also have been a confounder in the 
inability to find an association between FAM5C SNP rs10920501, MetS, and 
inflammatory biomarkers among women with documented CHD. The incidence of 
CHD varies between genders due to gender-specific genetic risk factors (Opstad, 
Pettersen, Weiss, Arnesen, & Seljeflot; Mercuro et al.; Tsai et al., 2009). The 
current study was composed of an all female sample, while GENECARD was a 
combined gender analysis (Hauser et al., 2004). The GENECARD sample was 
composed of approximately one-third women (Hauser et al.). The degree to 
which gender-gene exposures influence the findings can be difficult to assess 
and quantify (Liu et al., 2008). For example, Silander et al. (2008) evaluated 46 
candidate genes for CVD in a Finnish population and found that only half of the 
reported findings from combined gender analysis are true positives. Silander et 
al. suggests that genetic risk loci may be more readily detectable in women, 
while the results for men are confounded by lifestyle risk factors. Sex steroids 
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and gender-dependent gene expression have also been linked to the differences 
in the progression and extent of CHD between men and women. Lastly, 
traditional risk factors, such as hypertension, may also be influenced by gender-
specific factors (Mercuro et al., 2010). Ultimately, however, the contribution of the 
sex-specific differences beyond that of the traditional CHD risk factors remains 
unknown. Paynter et al. (2010) recently evaluated the contribution of genetic 
variation from 101 SNPs reported to be associated with CHD in 19,313 healthy 
white women in the Women’s Genome Health Study. They found that genetic risk 
score was not associated with CVD risk, and that self-reported family history 
remained the strongest predictor. Similarly, 9p21.3 (rs10757274) has been 
strongly and significantly associated with cardiovascular events, but knowledge 
of it has not significantly improved global risk prediction (Humphries, Ridker, & 
Talmud, 2004). Furthermore, the mechanism for disease manifestation through 
these genotypes remains largely unknown (Schunkert, Erdmann, & Samani, 
2010). The difference in which a particular gene contributes to the same 
phenotype in each of the sexes is an aspect that should be studied in more 
depth. A better understanding of the molecular basis of CHD prevalence and 
clinical manifestations represents a starting point for improved gender-oriented 
research.    
Finally, phenotypic heterogeneity can also be a confounding factor when 
trying to replicate a genetic association study. An association is considered to be 
replicated if the same SNP or haplotype is associated with the same phenotype 
in two or more populations (Peters, 2009). Phenotypic differences of CHD have 
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been found to be important in other genetic association studies. Girelli et al. 
(2007) investigated the role of ALOX5AP in the development of CHD and MI in 
patients with or without angiographically documented CHD. Girelli et al. 
examined 1,431 subjects, of whom 1,047 had severe coronary artery disease. 
The remaining 384 subjects had normal coronary arteries. The study sought an 
association with seven ALOX5AP SNPs and CHD, allowing for the reconstruction 
of at-risk haplotypes. Previously identified haplotypes were not replicated in the 
study. The investigators attributed this discrepancy to phenotypic heterogeneity, 
which is exacerbated by endemic nature of CHD in western populations. 
Previous studies focused on an MI phenotype versus controls from the 
general population. These controls were not stratified by angiography. Therefore, 
previous control populations could have had severe atherosclerotic lesions which 
were not yet clinically evident (Girelli et al.). The MI phenotype is not equal to the 
presence of CHD (Horne, Carlquist, Muhlestein, Bair, & Anderson, 2008). CHD 
may eventually progress to ACS and MI, but many patients can live with stable 
CHD that never progresses to an MI. The GENECARD ACS association subset 
defined inclusion by MI or ACS, as determined by a sentinel event or diagnostic 
study (Hauser et al., 2004). By contrast, the CATHGEN MI subset was limited to 
the documentation of an MI in the medical record (Connelly et al., 2008). This 
phenotypic heterogeneity in the setting of marginal p values calls into question if 
the FAM5C SNP had been previously replicated. The importance of stringent 
phenotypic criteria cannot be understated if the pathophysiologic mechanisms of 
CHD and MI are to be understood and eventually translated to clinical practice.  
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Aim three evaluated the association between FAM5C SNP rs10920501 
and early onset CHD in women. A supplemental analysis evaluated if there was 
an association between FAM5C SNP rs10920501 and age of onset of CHD in 
women who had ever experienced an MI. When the age of disease onset of the 
total sample was assessed by genotype, there was a trend toward a protective 
effect with the T allele, although it did not reach statistical significance. The 
homozygous variant (TT) genotype had on average the latest onset of CHD, and 
the homozygous wild type (AA) genotype had the earliest onset of CHD. The 
heterozygous (AT) was in the middle, creating a stepwise age stratification based 
on the presence of the T allele. Previous studies of FAM5C SNP rs10920501 
identified an earlier age of onset (< 55 years) for the subjects with the wild type A 
allele in the MI and ACS populations. Therefore, given the phenotypic 
heterogeneity in the current study, it was not surprising that the findings were not 
replicated utilizing the total sample of women with documented CHD. There was 
also evidence of different intermediate phenotypes when the current sample was 
age stratified. The younger women in the current sample with CHD were more 
likely to have familial heart disease and a previous history of smoking. 
Additionally, FAM5C SNP rs10920501 variant is relatively common. The minor 
allele frequency (MAF) of FAM5C SNP rs10920501 is .20 in the European (Utah 
residents with ancestry from northern and western Europe) population 
(International HapMap Project, 2008). The MAF is the frequency of the SNPs 
less frequent allele in a given population (Hartl & Jones, 2005). However, FAM5C 
SNP rs10920501 represents only one of hundreds or perhaps thousands of 
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SNPs that have a biological pathway to CHD. The possible gene-gene 
interaction, which is clearly plausible, can generate a rare composite-genotype 
from a common variant. For example, two relatively common SNPs, each with a 
MAF of 0.3, can produce an interacting genotype of 0.34 (= 0.0081), assuming 
independence and interaction among the minor homozygous alleles only 
(Pawitan, Seng, & Magnusson, 2009). The problem with interacting genotypes 
becomes more complicated if several SNPs are interacting. If distinct 
subphenotypes are due to different susceptibility genes, a study that combines 
them will have diluted effects. Additional variants, like CNV, insertion/deletion, or 
methylation status will be necessary to add to the prediction power in studies of 
complex diseases in the future (Pawitan, Seng, & Magnusson, 2009).   
In the supplemental analysis, age of disease onset was also assessed in 
women who had a history of an MI. Nearly two-thirds of women with a history of 
an MI had the homozygous wild type (AA) genotype, which is consistent with 
known genotyping frequencies. No women in this study with the homozygous 
variant (TT) had an MI, which supports the protective effective of the T allele. The 
major findings of this study are the confirmation of the protective effect of the 
FAM5C SNP (rs10920501) T allele in a population of women with a history of MI. 
Also, the homozygous wild type (AA) genotype is predictive of the age of CHD 
onset among women who have had an MI, when holding smoking history and 
BMI constant.  
To demonstrate the clinical relevance, consider two 40 year old women 
that are destined to have a MI. One woman has the homozygous wild type (AA) 
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genotype, and the other the heterozygous (AT) genotype. Can we predict which 
woman will have an MI first? Both women are smokers and have a BMI of 30, 
which are well established environmental risk factors for MI. The woman with the 
homozygous wild type (AA) genotype is predicted to have an MI 5.6 years before 
her counterpart. However, it must be noted that the genetic contribution was fairly 
small.   
To the best of our knowledge, the current study is the first to replicate the 
protective effective of the FAM5C SNP (rs10920501) T allele in a cohort of 
women. The linear regression suggests that genotype of FAM5C SNP 
rs10920501 exerted its effect on age of onset, independent of life style variables. 
Acknowledging the relatively small size in the MI subgroup, FAM5C SNP 
rs10920501 should be regarded as a relevant genetic determinant of the age of 
onset of CHD.    
Limitations 
 Limitations of the current study warrant consideration. All data were 
collected as part of the parent study. Therefore, any additional demographic  
variables were limited to those available in the parent study. The findings of this 
study are limited to a female population with documented CHD and cannot be 
generalized to the population at large. Since FAM5C has been linked to the MI 
phenotype, a subset was created from the total sample that had a limited sample 
size. This study was designed as an exploratory pilot, with a convenience 
sample, utilizing a single SNP. Lastly, CHD has been described as a 
manifestation of multiple intermediate disease processes, which individually have 
  71 
genetic and metabolic components (Lanktree & Hegele, 2009), not all of which 
could be addressed in this study. 
Conclusion   
FAM5C has shown promise as a novel MI susceptibility gene in the initial 
GENECARD study. Functional studies have been encouraging regarding the role 
the gene plays in the atherosclerotic process. Furthermore, FAM5C has 
demonstrated genetic overlap with MCP-1, MetS, and TNFSF4. The current 
study sought to elucidate interactions between FAM5C SNP rs10920501 and 
inflammatory biomarkers, and MetS, and early onset CHD. The current study 
demonstrated the protective benefit of the T allele in a limited sample size. The 
homozygous wild type (AA) was significantly associated with an earlier onset of 
CHD in women who had a history of an MI. The current study found no evidence 
of an association between FAM5C and hs-CRP, ICAM-1, IL-6, TNF-α, and MetS 
in an all-female cohort. The differences in study characteristics, outcomes 
evaluated, and potential gender-gene and gene-gene interactions may have 
contributed to the nonsignificant results. The current study contributes to the 
available body of knowledge, and since the inception of the current study there 
are many more candidate genes under study.  
It has been approximately five years since the first genome-wide 
association studies were published identifying a common risk allele with a large 
effect size for age-related macular degeneration. Initially, researchers were 
optimistic about the ability to detect disease with genome-wide association 
studies. Despite this, only a relatively small amount (< 10%) of the overall genetic 
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risk of coronary heart disease has been identified (Schunkert et al., 2010). The 
majority of risk alleles are common and have small effect sizes. Of these, only a 
small number of the risk alleles are non-synonymous SNPs in exons, which could 
alter protein structure and function. In fact, most risk alleles reside in either 
intron, intergenic, of desert gene regions. They may be functional SNPs, but little 
is known about their biological mechanism. Understanding these mechanisms is 
required before we can accurately model and measure complex traits.   
Phenomics will be of key importance in the post-GWAS era. Phenomics 
has been functionally defined as the systematic study of multiple phenotypes, 
across multiple biological scales (Lanktree & Hegele, 2009). It has become 
increasingly important as high-throughput genotyping drastically increased 
sample sizes, and new methods have enabled ever-finer mapping of genetic 
sequences to detect rare variants and CNV not captured on current platforms 
(Bilder et al., 2009). The application of phenomics requires a transdiscipline 
approach, which would include expertise in genetics, molecular biology, cell 
biology, systems biology, and the study of higher level phenotypic expression.  
While so far it remains unclear to what extent epigenetic factors contribute to 
phenotypic variance not explained by genomic data, the theoretical potential is 
vast (Bilder et al.). Phenomics will provide an increased understanding of CHD 
susceptibility and replication of gene-gene and gene-environment interactions 
(Lanktree & Hegele).  
Currently, traditional risk factors remain the greatest overall predictor of 
CHD. Even though a genotype may be strongly associated with CHD risk, if its 
  73 
mechanism is mediated through traditional risk factors, it is unlikely to add 
significantly to the overall risk prediction (Humphries, Ridker, & Talmud, 2004). 
Genotypes that have mechanisms outside traditional risk factors and that have a 
large effect are the most likely to add to risk prediction (Humphries et al.; Paynter 
et al., 2009). The genetic risk variants require a specific environment to 
contribute to disease. It is within that environment that there may be modifiable 
risk factors. A better understanding of these gene-gene, gender-gene, and gene-
environment interactions are vital to the understanding of the genetic 
predisposition to disease, which will aid prediction, prevention, diagnosis, and 
prognosis, and ultimately guide personalized medicine of CHD.     
Recommendations for Future Research 
FAM5C SNP rs10920501 has been associated with early onset CHD in 
women with a previous history of MI. It has been suggested that the mechanism 
is mediated through the initiation of smooth muscle cell proliferation and 
migration and/or in the disintegration of smooth muscle cells in the fibrous cap. 
Inflammation lies at the heart of this pathology and might explain the MCP-1 
linkage peak. Future research should explore the relationship between MCP-1 
and FAM5C more closely. Also, replication of gene expression in a female cohort 
or gender-specific data to confirm functional significance should be a priority. 
Ideally, these future gene expression studies would be large enough to allow for 
age stratification, which has not been possible in previous studies (Connelly et 
al.). Finally, the genetic pleiotropy of FAM5C could be investigated. FAM5C has 
been associated with MI, atrial fibrillation, and left atrial size (Connelly et al., 
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2008). These findings are in the setting on the known protective effect of the 
FAM5C SNP (rs10920501) T allele in a young population and evidence that 
FAM5C gene expression may play a role in senescence of smooth muscle cells 
(Connelly et al.). This begs the question of a possible antagonistic pleiotrophic 
effect with this SNP. The FAM5C gene may provide protection in early life, but 
have adverse effects later in life. Much more research is needed to address 
these questions. A better understanding of the genetically triggered pathogenesis 
of CHD and related interactions will open doors for additional research, risk 
prediction, and ultimately treatment.    
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